CN101591335B - N-(L-aminoacyl)-1, 2, 3, 4-tetrahydrochysene carboline acyl aminoacid benzyl ester, synthetic method and application thereof - Google Patents

N-(L-aminoacyl)-1, 2, 3, 4-tetrahydrochysene carboline acyl aminoacid benzyl ester, synthetic method and application thereof Download PDF

Info

Publication number
CN101591335B
CN101591335B CN2008101138564A CN200810113856A CN101591335B CN 101591335 B CN101591335 B CN 101591335B CN 2008101138564 A CN2008101138564 A CN 2008101138564A CN 200810113856 A CN200810113856 A CN 200810113856A CN 101591335 B CN101591335 B CN 101591335B
Authority
CN
China
Prior art keywords
tetrahydrocarboline
residue
boc
obzl
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008101138564A
Other languages
Chinese (zh)
Other versions
CN101591335A (en
Inventor
彭师奇
赵明
张建伟
周冬初
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Medical University
Original Assignee
Capital Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Medical University filed Critical Capital Medical University
Priority to CN2008101138564A priority Critical patent/CN101591335B/en
Publication of CN101591335A publication Critical patent/CN101591335A/en
Application granted granted Critical
Publication of CN101591335B publication Critical patent/CN101591335B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention discloses an N-(L-aminoacyl)-1, 2, 3, 4-tetrahydrochysene carboline acyl aminoacid benzyl ester compound with the antitumor effect, a preparation method and application thereof as an antitumor agent. The invention adopts an S180 mouse model to evaluate the antitumor activity of the compound. Experimental results show that the compound of the invention has excellent antitumor effect and can be clinically applied as the antitumor agent.

Description

N-(L-aminoacyl)-1,2,3,4-tetrahydrochysene carboline acyl aminoacid benzyl ester and compound method thereof and application
Technical field
The present invention relates to have the compound of anti-tumor activity; Relate in particular to N-(L-aminoacyl)-1 with anti-tumor activity; 2,3,4-tetrahydrochysene carboline acyl aminoacid benzyl ester compounds and preparation method thereof; The invention still further relates to the application of this compound in the preparation antitumor drug, belong to biomedicine field.
Background technology
Malignant tumour is a kind of common disease and frequently-occurring disease of serious threat human health, and the mortality ratio that the mankind cause because of malignant tumour is second of all disease death rates, is only second to cardiovascular and cerebrovascular diseases.The tumor treatment method has operative treatment, radiotherapy and pharmacological agent (chemotherapy).At present, chemotherapy remains the main means of clinical treatment tumour.Seeking antitumor drug is one of focus of new drug research.The contriver recognizes, introduces amino acid and 3 carboxyls at 2 N of β-Ka Lin-3-carboxylic acid and introduces the amino acid benzyls and possibly produce antitumor action.
Summary of the invention
One of the object of the invention provides one type of new compound with anti-tumor activity.
Two of the object of the invention provides a kind of above-mentioned method with compound of anti-tumor activity for preparing.
Three of the object of the invention provides a kind of pharmaceutical composition with antitumor efficacy.
Above-mentioned purpose of the present invention realizes through following technical scheme:
Compound with anti-tumor activity, the structural formula of this compound are shown in general formula I or the general formula I I:
Figure S2008101138564D00011
general formula I
Wherein, AA 1Be selected from L-Ala (Ala) residue, glycocoll (Gly) residue, proline(Pro) (Pro), Stimulina (Gln) residue, leucine (Leu) residue, phenylalanine(Phe) (Phe) residue, Isoleucine (Ile) residue, methionine(Met) (Met) residue, tyrosine (Tyr) residue, tryptophane (Trp) residue, Xie Ansuan (Val) residue, Methionin (Lys) residue, Arg (NO 2), Thr (Bzl), Ser (Bzl) or Cys (CH 2-C 6H 4-OCH 3); AA 2Be selected from L-Ala (Ala) residue, glycocoll (Gly) residue, proline(Pro) (Pro) residue, Stimulina (Gln) residue, leucine (Leu) residue, phenylalanine(Phe) (Phe) residue, Isoleucine (Ile) residue, methionine(Met) (Met) residue, tyrosine (Tyr) residue, tryptophane (Trp) residue, Xie Ansuan (Val) residue, Methionin Lys (Z), Arg (NO 2), Thr (Bzl), Ser (Bzl) or Cys (But);
Figure S2008101138564D00021
general formula I I
Wherein, AA 1Be selected from Asp (OBZl) or Glu (OBZl); AA 2Be selected from Asp (OBZl) or Glu (OBZl);
A kind of method for preparing above-mentioned compound of Formula I, this method comprises:
(1) the L-tryptophan transfer is become 1,2,3,4-Tetrahydrocarboline carboxylic acid;
(2) with 1,2,3,4-Tetrahydrocarboline carboxylic acid changes carboline carboxylate benzyl ester into;
(3) in the presence of tosic acid and benzylalcohol, amino acid is changed into amino-acid benzyl ester (2);
(4) at (Boc) 2O and NaOH exist down, and amino acid changes into N-t-butoxycarbonyl amino acid (1);
(5) with the acid of N-t-butoxycarbonyl amino and 1,2,3, the condensation of 4-Tetrahydrocarboline benzyl carboxylate generates N-t-butoxycarbonyl amino acyl-1,2,3,4-Tetrahydrocarboline benzyl carboxylate;
(6) with N-t-butoxycarbonyl amino acyl-1,2,3,4-Tetrahydrocarboline benzyl carboxylate hydrogenolysis generates N-t-butoxycarbonyl amino acyl-1,2,3,4-Tetrahydrocarboline carboxylic acid;
(7) with N-t-butoxycarbonyl amino acyl-1,2,3, the hydrolysis of 4-Tetrahydrocarboline benzyl carboxylate generates N-t-butoxycarbonyl amino acyl-1,2,3,4-Tetrahydrocarboline carboxylic acid;
(8) with N-t-butoxycarbonyl amino acyl-1,2,3,4-Tetrahydrocarboline carboxylic acid and amino-acid benzyl ester condensation generate N-t-butoxycarbonyl amino acyl-1,2,3, the 4-tetrahydrochysene carboline acyl aminoacid benzyl ester;
(9) with N-t-butoxycarbonyl amino acyl-1,2,3, the acidolysis of 4-tetrahydrochysene carboline acyl aminoacid benzyl ester promptly gets.
Among the above-mentioned preparation method, the amino-acid benzyl ester described in the step (3) is selected from Ala-OBzl, Gly-OBzl, Pro-OBzl, Gln-OBzl, Leu-OBzl, Phe-OBzl, Ile-OBzl, Met-OBzl, Tyr-OBzl, Trp-OBzl, Val-OBzl, Lys (Z)-OBzl, Arg (NO 2)-OBzl, Thr (Bzl)-OBzl, Ser (Bzl)-OBzl, Cys (But)-OBzl, Asp (OBzl)-Obzl or Glu (OBzl)-OBzl;
N-t-butoxycarbonyl amino acid described in the step (4) is selected from N-Boc-Ala, N-Boc-Gly, N-Boc-Pro, N-Boc-Gln, N-Boc-Leu, N-Boc-Phe, N-Boc-Ile, N-Boc-Met, N-Boc-Tyr, N-Boc-Trp, N-Boc-Val, N-Boc-Lys, N-Boc-Arg (NO 2), N-Boc-Thr (Bzl), N-Boc-Ser (Bzl), N-Boc-Cys (CH 2-C 6H 4-OCH 3), N-Boc-Asp (OBzl) or N-Boc-Glu (OBzl);
A kind of method for preparing above-mentioned general formula I I compound, this method comprises:
(1) the L-tryptophan transfer is become 1,2,3,4-Tetrahydrocarboline carboxylic acid;
(2) with 1,2,3,4-Tetrahydrocarboline carboxylic acid is transformed into N-tertbutyloxycarbonyl-1,2,3,4-Tetrahydrocarboline carboxylic acid;
(3) with N-N-tertbutyloxycarbonyl-1,2,3,4-Tetrahydrocarboline carboxylic acid and amino-acid benzyl ester condensation generate N-N-tertbutyloxycarbonyl-1,2,3, the 4-tetrahydrochysene carboline acyl aminoacid benzyl ester;
(4) with N-N-tertbutyloxycarbonyl-1,2,3, the acidolysis of 4-tetrahydrochysene carboline acyl aminoacid benzyl ester generates 1,2,3, the 4-tetrahydrochysene carboline acyl aminoacid benzyl ester;
(5) with the acid of N-t-butoxycarbonyl amino and 1,2,3, the condensation of 4-tetrahydrochysene carboline acyl aminoacid benzyl ester generates N-N-t-butoxycarbonyl amino acyl-1,2,3, the 4-tetrahydrochysene carboline acyl aminoacid benzyl ester;
(6) with N-N-t-butoxycarbonyl amino acyl-1,2,3, the acidolysis of 4-tetrahydrochysene carboline acyl aminoacid benzyl ester promptly gets.
Wherein, the amino-acid benzyl ester described in the step (3) is selected from Asp (OBZl)-OBzl or Glu (OBZl)-OBzl; N-t-butoxycarbonyl amino acid described in the step (5) is selected from N-Boc-Asp (OBZl) or N-Boc-Glu (OBZl)
Another purpose of the present invention provides a kind of medicinal compsns with anti-tumor activity; General formula I of the present invention or general formula I I compound and pharmaceutically acceptable carrier that this medicinal compsns is gone up effective dose by treatment are formed; General formula I of the present invention or the general formula I I compound that is about to significant quantity be with after pharmaceutically acceptable carrier or thinner cooperate, and by the formulation method of this area routine it is prepared into any one appropriate drug compsn.Usually said composition is suitable for oral administration and drug administration by injection, also is fit to other medication.Said composition can be liquid preparation forms such as tablet, capsule, pulvis, granule, lozenge, suppository, or oral liquid.According to different medications, pharmaceutical composition of the present invention can contain 0.1%-99% weight, the The compounds of this invention of preferred 10-60% weight.
The present invention is at mouse S 180Estimate the anti-tumor activity of general formula I of the present invention and general formula I I compound on the sarcoma model, test-results shows that general formula I of the present invention and general formula I I compound have definite anti-tumor activity.
Description of drawings
The structure iron of Fig. 1 general formula compound of the present invention.
The synthetic route chart of Fig. 2 compound of Formula I; I) formaldehyde and the vitriol oil, stirring at room; Ii) benzylalcohol, polyphosphoric acid, oil bath are 90 ℃; Iii) Boc-AA 1, DCC, HoBt, NMM; Iv-1) Pd/C, H 2, ethanol AA 1Be selected from Ala, Gly, Pro, Gln, Leu, Phe, Ile, Tyr, Trp, Val, Lys (Boc); Iv-2) 2N NaOH, methyl alcohol AA 1Be selected from Met, Arg (NO 2), Thr (Bzl), Ser (Bzl), Cys (CH 2-C 6H 4-OCH 3); V) L-AA 2-OBzl, DCC, HoBt, NMM; Vi) 4N hydrogenchloride-ethyl acetate solution; AA among the 7a-p 1Be selected from Ala, Gly, Pro, Gln, Leu, Phe, Ile, Met, Tyr, Trp, Val, Lys (Boc), Arg (NO 2), Thr (Bzl), Ser (Bzl), Cys (CH 2-C 6H 4-OCH 3); AA 2Be selected from Ala, Gly, Pro, Gln, Leu, Phe, Ile, Met, Tyr, Trp, Val, Lys (Z), Arg (NO 2), Thr (Bzl), Ser (Bzl), Cys (But); AA among the 8a-p 1Be selected from Ala, Gly, Pro, Gln, Leu, Phe, Ile, Met, Tyr, Trp, Val, Lys, Arg (NO 2), Thr (Bzl), Ser (Bzl), Cys (CH 2-C 6H 4-OCH 3); AA 2Be selected from Ala, Gly, Pro, Gln, Leu, Phe, Ile, Met, Tyr, Trp, Val, Lys (Z), Arg (NO 2), Thr (Bzl), Ser (Bzl), Cys (But).
The synthetic route chart of Fig. 3 general formula I I compound; I) formaldehyde and the vitriol oil, stirring at room; Ii) (Boc) 2O, triethylamine, DMF; Iii) DCC, HOBt, AAOBzl, anhydrous THF; Iv) 4N HCl-EtoAC; V) DCC, HOBt, Boc-AA-OH, anhydrous THF; Vi) 4N HCl-EtoAC; 5q, AA is selected from Asp (OBzl) or Glu (OBzl) among the r; 6q, AA is selected from Asp (OBzl) or Glu (OBzl) among the r; 7q, AA among the r 1Be selected from Asp (OBzl) or Glu (OBZl), AA 2Be selected from Asp (OBzl) or Glu (OBZl); 8q, AA among the r 1Be selected from Asp (OBZl) or Glu (OBZl), AA 2Be selected from Asp (OBZl) or Glu (OBZl).
Embodiment
In order further to set forth the present invention, provide a series of instances below.These instances are illustrative fully, and they only are used for the present invention is specifically described, and are not to be understood that to be limitation of the present invention.
Embodiment 11, and 2,3,4-Tetrahydrocarboline-3-carboxylic acid (2)
400ml water is placed the round-bottomed flask of 500ml; Slowly adding the 0.2ml vitriol oil shakes up. in the dilution heat of sulfuric acid that obtains, add 5.0g (24.5mmol) L-tryptophane. dissolve fully with sonic oscillation to L-tryptophane; Add 10ml concentration in the solution that obtains and be 35% formaldehyde, stir, the TLC plate detects L-tryptophane raw material point disappearance termination reaction. slow dropping ammonia accent pH value to 6 in the reaction solution; Static half hour; Decompression leaches the deposition of generation, the colorless solid drying that the water flushing the leaches 5.01g that weighs, productive rate: 95%.M.p.229-231℃，ESI-MS(m/z)：[M+H] +217。
Embodiment 2 2-Boc-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (3)
With 1g (4.63mmol) 1,2,3,4-Tetrahydrocarboline-3-carboxylic acid is suspended in and contains 1.2g (Boc) under the ice bath 2In the 10mlDMF solution of O (5.50mmol); Add triethylamine then and transfer the PH8-9 reaction, along with the solution that carries out suspendible that reacts becomes clarification gradually, solution colour is yellow; TLC plate detection reaction (chloroform: raw material point disappearance stopped reaction methyl alcohol=10: 1); Electric fan dries up DMF, the residue dissolving after will drying up with ETHYLE ACETATE, 5% KHSO 4Wash saturated NaCl washing 3 times, anhydrous Na 3 times 2SO 4Drying is filtered, and the evaporate to dryness residue obtains target compound 958mg with the chloroform washing, colorless solid, and productive rate: 65.5%, Mp:241-243 ℃; [α] D 25=64.43 (C1; Methyl alcohol) .ESI-MS (m/z) 317 [M+H] + 1H NMR (500MHz, DMSO-d 6): δ/ppm=12.794 (s, 1H), 10.887 (d, J=23.5Hz, 1H), 7.293-7.440 (m, J=8Hz, J=7.5Hz; 2H), 6.969-7.077 (m, J=7Hz, J=7.5Hz, 2H), 5.1245 (dd, J=5.5Hz, 1H); 4.742 (t, J=17Hz, J=19Hz, H), 4.4195 (dd, J=20Hz, 1H), 3.323 (m; J=7.5Hz, 1H), 2.985 (m, J=6.5Hz, 1H), 1.460 (s, 9H). 13CNMR (DMSO-d 6): δ/ppm=173.28,155.56,136.66,130.81,126.76,121.41,119.01,118.03,111.47,104.99,80.27,60.20,53.86,28.49,23.34.
Embodiment 31, and 2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (4)
Get 20ml benzylalcohol and the 2g polyphosphoric acid makes it to dissolve each other, 70 ℃ of oil baths add carboline carboxylate 1g and begin insoluble; Reaction solution is that yellow-green colour is warming up to 90 ℃ of reaction solutions and dissolves gradually and become the clarification color and turn brown gradually, TLC plate detection reaction, and 24 hours raw material points disappear and carry out aftertreatment. cool off; Add the 50ml ether and fully stir with 70ml water and crystallization occurs, filtration, ether water is washed the carboline carboxylate benzyl ester phosphoric acid salt that obtains yellow-white repeatedly. with the carboline carboxylate benzyl ester phosphoric acid salt DL that obtains in ETHYLE ACETATE; Drip triethylamine to clarification, with 5% sodium hydrogencarbonate washing 6 times, saturated sodium-chloride washing 3 times; Anhydrous sodium sulfate drying filters, and revolves dried; Obtain the carboline carboxylate benzyl ester 0.85g of yellow-white, productive rate 60%; Mp122-124 ℃; [α] D 25=53.4 (C1; Methyl alcohol); ESI-MS (m/z): 307 [M+H] + 1H NMR (500MHZ, DMSO-d 6): δ/ppm=7.275-7.401 (m, 7H), 6.951 (t, J=7.5Hz, 1H), 7.025 (t; J=10Hz, 1H), 5.191 (s, 2H), 3.9885 (q, J=15.5Hz; 2H), 3.824 (q, J=4.5Hz, J=8.5Hz, 1H), 2.9765 (dd; J=4.5Hz, J=15Hz, 1H), 2.815 (q, J=8.5Hz, J=15Hz). 13CNMR (DMSO-d 6): δ/ppm=173.21,136.57,136.23,133.46,128.90,128.71,128.46,128.21,127.30,120.97,118.79,117.73,111.33,105.83,66.15,55.63,41.7,25.26.
Embodiment 4 N-Boc-Ala-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5a)
Ice bath dissolves 1.229g (6.5mmol) Boc-Ala with anhydrous THF down; Add 0.921g (6.82mmol) N-hydroxy benzo triazole (HOBt); The dissolving back added 1.74lg (8.45mmol) dicyclohexyl carbonyl diimine (DCC) after .10 minute fully, added anhydrous THF and 1.53g (5.0mmol) 1,2 inward; 3,4-Tetrahydrocarboline-3-benzyl carboxylate is also transferred the solution between the pH value 8-9 with N-methylmorpholine.Reaction mixture stirs, and the detection of TLC plate (oil mystery/acetone, 3: 1, Rf=0.2).Raw material point leaches NSC 30023 (DCU) after disappearing, and filtrate decompression concentrates, and residue is used the 40ml acetic acid ethyl dissolution.The solution that obtains is used saturated NaHCO successively 3, saturated NaCl, 5%KHSO 4, saturated NaCl, saturated NaHCO 3, saturated NaCl respectively gives a baby a bath on the third day after its birth time to neutral anhydrous Na 2SO 4Dry.Filter, filtrate decompression is concentrated into dried, obtains 1.761g (74%) title compound (faint yellow solid).Mp87-90 ℃; [α] D 25=27.33 (C=1.0, methyl alcohol).ESI-MS(m/z)478[M+H] +。
Embodiment 5 N-Boc-Gly-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5b)
According to the operation of preparation 5a, from 0.91g (5.2mmol) Boc-Gly and 1.224g (4.0mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 1.48g (79.9%) title compound (faint yellow solid).Mp102-104 ℃; [α] D 25=19.47 (C=1.0, methyl alcohol); ESI-MS (m/z) 464 [M+H] +
Embodiment 6 N-Boc-Pro-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5c)
According to the operation of preparation 5a, from 1.18g (5.2mmo1) Boc-Pro and 1.224g (4.0mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.372g (19%) title compound (yellow solid).Mp88-90 ℃; [α] D 25=-2.70 (C=1.0, methyl alcohol); ESI-MS (m/z) 504 [M+H] +
Embodiment 7 N-Boc-Gln-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5d)
According to the operation of preparation 5a, from 0.949g (6.5mmol) Boc-Gln and 1.53g (5.0mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 1.0g (37%) title compound (colorless solid).Mp102-104 ℃; [α] D 25=74 (C=1.0, methyl alcohol); ESI-MS (m/z) 535 [M+H] +
Embodiment 8 N-Boc-Leu-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5e)
According to the operation of preparation 5a, from 1.201g (5.2mmol) Boc-Leu and 1.224g (4.0mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 1.654g (80%) title compound (colorless solid).Mp84-86 ℃; [α] D 25=38.5 (C=1.0; Methyl alcohol); ESI-MS (m/z) 520 [M+H] +
Embodiment 9 N-Boc-Phe-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5f)
According to the operation of preparation 5a, from 1.378g (5.2mmol) Boc-Phe and 1.224g (4.0mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 2.033g (92%) title compound (colorless solid).Mp74-76 ℃; [α] D 25=53.0 (C=1.0, methyl alcohol); ESI-MS (m/z) 554 [M+H] +
Embodiment 10 N-Boc-Ile-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5g)
According to the operation of preparation 5a, from 1.502g (6.5mmol) Boc-Ile and 1.53g (5.0mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 1.90g (73%) title compound (colorless solid).Mp 78-81 ℃; [α] D 25=46.7 (C=1.0, methyl alcohol); ESI-MS (m/z) 542 [M+H] +
Embodiment 11 N-Boc-Met-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5h)
According to the operation of preparation 5a, from 1.618g (6.5mmol) Boc-Met and 1.53g (5.0mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 1.69g (63%) title compound (yellow solid).Mp76-78 ℃; [α] D 25=46.9 (C=1.0, methyl alcohol); ESI-MS (m/z) 538 [M+H] +
Embodiment 12 N-Boc-Tyr-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5i)
According to the operation of preparation 5a, from 1.826g (6.5mmol) Boc-Tyr and 1.53g (5.0mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.747g (26%) title compound (yellow solid).Mp102-103 ℃; [α] D 25=48.1 (C=1.0, methyl alcohol); ESI-MS (m/z) 592 [M+H] +
Embodiment 13 N-Boc-Trp-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5j)
According to the operation of preparation 5a, from 1.58g (5.2mmol) Boc-Trp and 1.224g (4.0mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 1.80g (76%) title compound (colorless solid).Mp102-104 ℃; [α] D 25=56.5 (C=1.0, methyl alcohol); ESI-MS (m/z) 593 [M+H] +
Embodiment 14 N-Boc-Val-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5k)
According to the operation of preparation 5a, from 1.128g (5.2mmol) Boc-Val and 1.224g (4.0mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 1.403g (69%) title compound (yellow solid).Mp72-74 ℃; [α] D 25=80.6 (C=1.0; Methyl alcohol); ESI-MS (m/z) 506 [M+H] +
Embodiment 15 N-Boc-Lys (Boc)-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5l)
According to the operation of preparation 5a, from 1.799g (5.2mmol) Boc-Lys (Boc) and 1.224g (4.0mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 2.298g (91%) title compound (yellow solid).Mp78-79 ℃; [α] D 25=40.2 (C=1.0, methyl alcohol); ESI-MS (m/z) 635 [M+H] +
Embodiment 16 N-Boc-Arg (NO 2)-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5m)
According to the operation of preparation 5a, from 0.957g (3.0mmol) Boc-Arg (NO 2) and 0.765g (2.5mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.90g (59%) title compound (yellow solid).Mp 118-121 ℃; [α] D 25=42.1 (C=1.0, methyl alcohol); ESI-MS (m/z) 608 [M+H] +
Embodiment 17 N-Boc-Thr (Bzl)-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5n)
According to the operation of preparation 5a, from 0.927g (3.0mmol) Boc-Thr (Bzl) and 0.765g (2.5mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.90g (60%) title compound (colorless solid).Mp148-150 ℃; [α] D 25=46.3 (C=1.0, methyl alcohol); ESI-MS (m/z) 598 [M+H] +
Embodiment 18 N-Boc-Ser (Bzl)-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5o)
According to the operation of preparation 5a, from 0.885g (3.0mmol) Boc-Ser (Bzl) and 0.765g (2.5mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 1.075g (74%) title compound (colorless solid).Mp 66-68 ℃; [α] D 25=38.9 (C=1.0, methyl alcohol); ESI-MS (m/z) 584 [M+H] +
Embodiment 19 N-Boc-Cys (CH 2-C 6H 4-OCH 3)-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate (5p)
According to the operation of preparation 5a, from 1.228g (3.6mmol) Boc-Cys (CH 2-C 6H 4-OCH 3) and 0.918g (3.0mmol) 1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 1.30g (69%) title compound (colorless solid).Mp50-53 ℃; [α] D 25=13.0 (C=1.0, methyl alcohol); ESI-MS (m/z) 630 [M+H] +
Embodiment 20 N-Boc-1,2,3,4-Tetrahydrocarboline-3-formyl-Asp (OBzl)-OBzl (5q)
According to the operation of preparation 5a, from 0.632g (2.0mmol) N-Boc-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid and 1.067g (2.2mmol) Asp (OBzl)-OBz get 0.657g (54%) title compound (colorless solid).Mp 50-52 ℃; [α] D 25=29.7 (C=1.0, methyl alcohol); ESI-MS (m/z) 612 [M+H] +
Embodiment 21 N-Boc-1,2,3,4-Tetrahydrocarboline-3-formyl-Glu (OBzl)-OBzl (5r)
According to the operation of preparation 5a, from 0.632g (2.0mmol) N-Boc-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid and 1.10g (2.2mmol) Glu (OBzl)-OBzl get 0.671g (54%) title compound (colorless solid).Mp53-56 ℃; [α] D 25=20.5 (C=1.0, methyl alcohol); ESI-MS (m/z) 626 [M+H] +
Embodiment 22 N-Boc-Ala-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6a)
In the round-bottomed flask of 100ml, with the 20ml absolute ethyl alcohol with 1.6g (3.35mmol) N-Boc-Ala-1,2,3, the dissolving of 4-Tetrahydrocarboline-3-benzyl carboxylate adds 0.8gPd/C, feeds H 2Stirring reaction, TLC detect raw material point and disappear termination reaction; Filter Pd/C, the evaporate to dryness mother liquor gets 1.23g (95%) title compound (colorless solid).Mp148-150 ℃; [α] D 25=55.3 (C=1.0, methyl alcohol); ESI-MS (m/z) 386 [M-H] -
Embodiment 23 N-Boc-Gly-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6b)
According to the operation of preparation 6a, from 1.2g (2.59mmol) N-Boc-Gly-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.956g (99%) title compound (colorless solid).Mp142-144 ℃; [α] D 25=63.2 (C=1.0, methyl alcohol); ESI-MS (m/z) 370 [M-H] -
Embodiment 24 N-Boc-Pro-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6c)
According to the operation of preparation 6a, from 0.370g (0.74mmol) N-Boc-Pro-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.364g (97%) title compound (colorless solid).Mp167-169 ℃; [α] D 25=-12.5 (C=1.0, methyl alcohol); ESI-MS (m/z) 412 [M-H] -
Embodiment 25 N-Boc-Gln-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6d)
According to the operation of preparation 6a, from 1.0g (1.873mmol) N-Boc-Gln-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.80g (96%) title compound (colorless solid).Mp151-153 ℃; [α] D 25=71.7 (C=1.0, methyl alcohol); ESI-MS (m/z) 443 [M-H] -
Embodiment 26 N-Boc-Leu-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6e)
According to the operation of preparation 6a, from 1.0g (1.93mmol) N-Boc-Leu-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.786g (95%) title compound (colorless solid).Mp142-144 ℃; [α] D 25=64.1 (C=1.0, methyl alcohol); ESI-MS (m/z) 428 [M-H] -
Embodiment 27 N-Boc-Phe-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6f)
According to the operation of preparation 6a, from 0.676g (1.222mmol) N-Boc-Phe-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.534g (94%) title compound (colorless solid).Mp136-138 ℃; [α] D 25=58.8 (C=1.0, methyl alcohol); ESI-MS (m/z) 462 [M-H] -
Embodiment 28 N-Boc-Ile-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6g)
According to the operation of preparation 6a, from 1.0g (1.222mmol) N-Boc-Ile-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.819g (99%) title compound (colorless solid).Mp145-146 ℃; [α] D 25=55.0 (C=1.0, methyl alcohol); ESI-MS (m/z) 428 [M-H] -
Embodiment 29 N-Boc-Met-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6h)
With 1.2g (2.235mmol) N-Boc-Met-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate is dissolved in 4ml methyl alcohol, splashes into the 3ml 2N NaOH aqueous solution and is stirred to the disappearance of raw material point, termination reaction to the solution that obtains under the ice bath.Compound of reaction is used saturated KHSO 4Transfer pH6-7, concentrating under reduced pressure is removed steaming methyl alcohol.Residue is used saturated KHSO 4Transfer pH1-2, ethyl acetate extraction 3 times, the combined ethyl acetate layer is washed 3 times with the saturated NaCl aqueous solution, and ethyl acetate layer is used anhydrous Na 2SO 4Drying is filtered, and is evaporated to dried 0.849g (85%) title compound (colorless solid).Mp104-106 ℃; [α] D 25=48.7 (C=1.0, methyl alcohol); ESI-MS (m/z) 446 [M+H] +
Embodiment 30 N-Boc-Tyr-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6i)
According to the operation of preparation 6a, from 0.720g (1.265mmol) N-Boc-Tyr-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.569g (94%) title compound (colorless solid).Mp166-168 ℃; [α] D 25=51.7 (C=1.0, methyl alcohol); ESI-MS (m/z) 478 [M-H] -
Embodiment 31 N-Boc-Trp-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6j)
According to the operation of preparation 6a, from 1.170g (1.976mmol) N-Boc-Trp-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.962g (97%) title compound (colorless solid).Mp168-169 ℃; [α] D 25=72.5 (C=1.0, methyl alcohol); ESI-MS (m/z) 501 [M-H] -
Embodiment 32 N-Boc-Val-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6k)
According to the operation of preparation 6a, from 1.403g (2.780mmol) N-Boc-Val-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 1.130g (98%) title compound (colorless solid).Mp139-141 ℃; [α] D 25=66.2 (C=1.0, methyl alcohol); ESI-MS (m/z) 414 [M-H] -
Embodiment 33 N-Boc-Lys (Boc)-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6l)
According to the operation of preparation 6a, from 1.0g (1.577mmol) N-Boc-Lys (Boc)-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.849g (99%) title compound (colorless solid).Mp123-125 ℃; [α] D 25=18.6 (C=1.0, methyl alcohol); ESI-MS (m/z) 543 [M-H] -
Embodiment 34 N-Boc-Arg (NO 2)-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6m)
According to the operation of preparation 6h, from 1.5g (2.479mmol) N-Boc-Arg (NO 2)-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 1.153g (90%) title compound (colorless solid).Mp170-172 ℃; [α] D 25=27.7 (C=1.0, methyl alcohol); ESI-MS (m/z) 516 [M-H] -
Embodiment 35 N-Boc-Thr (Bzl)-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6n)
According to the operation of preparation 6h, from 1.0g (1.675mmol) N-Boc-Thr (Bzl)-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.789g (93%) title compound (colorless solid).Mp89-92 ℃; [α] D 25=39.1 (C=1.0, methyl alcohol); ESI-MS (m/z) 506 [M-H] -
Embodiment 36 N-Boc-Ser (Bzl)-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6o)
According to the operation of preparation 6h, from 1.105g (1.895mmol) N-Boc-Ser (Bzl)-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 0.925g (99%) title compound (colorless solid).Mp53-55 ℃; [α] D 25=30.9 (C=1.0, methyl alcohol); ESI-MS (m/z) 492 [M-H] -
Embodiment 37 N-Boc-Cys (CH 2-C 6H 4-OCH 3)-1,2,3,4-Tetrahydrocarboline-3-carboxylic acid (6p)
According to the operation of preparation 6h, from 1.20g (1.908mmol) N-Boc-Cys (CH 2-C 6H 4-OCH 3)-1,2,3,4-Tetrahydrocarboline-3-benzyl carboxylate gets 1.0g (97%) title compound (colorless solid).Mp44-46 ℃; [α] D 25=-47.4 (C=1.0, methyl alcohol); ESI-MS (m/z) 538 [M-H] -
Embodiment 38 1, and 2,3,4-Tetrahydrocarboline-3-acyl group-Asp (OBzl)-OBzl (6q)
In the round-bottomed flask of 100ml, with 1ml ETHYLE ACETATE with 0.657g (1.075mmol) N-Boc-1,2; 3; 4-Tetrahydrocarboline-3-acyl group-Asp (OBzl)-OBzl dissolving under the condition of ice bath, adds 2ml 4N HCl/ ETHYLE ACETATE stirring reaction; TLC plate detection reaction, termination reaction when raw material point disappears.Drain mother liquor, add ether and obtain 0.581g (98.6%) title compound (yellow solid) repeatedly for 3 times.M.p.93-95 ℃; [α] D 25=-55.5 (C=1.0, methyl alcohol); ESI-MS (m/z): 512.5 [M+H] +
Embodiment 39 1, and 2,3,4-Tetrahydrocarboline-3-acyl group-Glu (OBzl)-OBzl (6r)
According to the operation of preparation 6q, from 0.671g (1.074mmol) N-Boc-1,2,3,4-Tetrahydrocarboline-3-acyl group-Glu (OBzl)-OBzl obtains 0.602g (99%) title compound (yellow solid).Mp108-110 ℃; [α] D 25=-57.0 (C=1.0, methyl alcohol); ESI-MS (m/z): 526.5 [M+H] +
Embodiment 40 Boc-Ala-1,2,3,4-Tetrahydrocarboline-3-acyl group-Ala-OBzl (7a)
Ice bath descends with anhydrous THF 0.776g (2.0mmol) Boc-Ala-1; 2; 3, the dissolving of 4-Tetrahydrocarboline carboxylic acid adds 0.284g (2.104mmol) N-hydroxy benzo triazole (HOBt); The dissolving back added 0.536g (2.60mmol) dicyclohexyl carbonyl diimine (DCC) after .10 minute fully, added anhydrous THF and 0.913g (2.60mmol) Ala-OBzl inward and transferred the solution between the pH value 8-9 with N-methylmorpholine.Reaction mixture stirs, and the detection of TLC plate (oil mystery/acetone, 3: 1, Rf=0.35).Raw material point leaches NSC 30023 (DCU) after disappearing, and filtrate decompression concentrates, and residue is used the 40ml acetic acid ethyl dissolution.The solution that obtains is used saturated NaHCO successively 3, saturated NaCl, 5%KHSO 4, saturated NaCl, saturated NaHCO 3, saturated NaCl respectively gives a baby a bath on the third day after its birth time to neutral anhydrous Na 2SO 4Dry.Filter, filtrate decompression is concentrated into dried, obtains 0.709g (64.7%) title compound (colorless solid).M.p.:113-115.80 ℃; [α] D 25=-5.6 (C=1.0, methyl alcohol); ESI-MS (m/z): 549.4 [M+H] +IR(KBr)：3313，2978，2931，1739，1678，1647，1520，1452，1246，1163，1065，744，693. 1H?NMR(500MHz，DMSO-d 6)：δ/ppm＝10.806(s，1H)，8.374(t，J＝8.5Hz，1H)，7.094-7.439(m，7H)，7.05(t，J＝7Hz，1H)，6.9725(t，J＝6.5Hz，1H)，4.167-5.635(m，7H)，3.372(q，J＝15.5Hz，J＝46.5Hz，1H)，2.9285(m，J＝6Hz，1H)，1.405(s，9H)，1.225-1.338(m，6H). 13CNMR(DMSO-d 6)：δ/ppm＝172.58，172.43，171.10，156.22，155.50，136.34，130.17，128.79，128.35，128.07，126.93，121.26，118.90，111.43，105.03，79.00，78.63，66.22，48.63，33.81，28.62，24.92，23.41，17.15.
Embodiment 41 Boc-Gly-1,2,3,4-Tetrahydrocarboline-3-acyl group-Gly-OBzl (7b)
According to the operation of preparation 7a, from 0.590g (1.582mmol) Boc-Gly-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.452g (54.95%) title compound (colorless solid).TLC (sherwood oil/acetone, 3: 1, Rf=0.4); Mp114-116 ℃; [α] D 25=49.9 (C=1.0, methyl alcohol); ESI-MS (m/z): 521.6 [M+H] +[543.6 M+Na] +.IR (KBr): 3396,3302,2976,2931,1751,1685,1647,1521,1452,1390,1367,1161,744,690. 1H NMR (300MHz, DMSO-d 6): δ/ppm=10.817 (s, 1H), 8.4425 (m, J=5.4Hz, J=5.7Hz 1H), 7.3895 (d, J=7.5Hz, 1H); 7.258-7.377 (m, 6H), 7.047 (t, J=7.2Hz, 1H), 6.9655 (t, J=6.9Hz; 1H), and 4.329-5.021 (m, 5H), 3.739-4.164 (m, 4H), 3.3935 (m, J=2.7Hz; 1H), 2.9195 (dd, J=5.7Hz, J=15.9Hz, 1H), 1.404 (s, 9H). 13CNMR (DMSO-d 6): δ/ppm=171.04,170.61,170.56,156.22,136.77,136.52,130.58,129.85; 128.84,128.46,128.35,126.98,118.93,111.54,105.39,78.58; 66.34,65.36,54.25,42.96,41.51,28.70,22.74.
Embodiment 42 Boc-Pro-1,2,3,4-Tetrahydrocarboline-3-acyl group-Pro-OBzl (7c)
According to the operation of preparation 7a, from 0.174g (0.421mmol) Boc-Pro-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.110g (43.5%) title compound (colorless solid).TLC (sherwood oil/acetone, 3: 1, Rf=0.2); Mp100-103 ℃; [α] D 25=-156.2 (C=1.0, methyl alcohol); ESI-MS (m/z): 623.3 [M+Na] +[523.4 M+Na-Boc] +IR(KBr)：3330，2938，2850，1739，1689，1647，1452，1409，1165，743，693.
1H?NMR(500MHz，CDCl3-d 6)：δ/ppm＝7.140-7.560(m，7H)，7.029-7.067(m，2H)，4.489-5.410(m，7H)，4.333(m，1H)，4.176(q，J＝4.5Hz，J＝11.5Hz，1H)，4.032(q，J＝3.5Hz，J＝6Hz，1H)，3.9125(q，J＝6.5Hz，J＝10.5Hz，1H)，3.430(m，J＝16Hz，1H)，2.827(dd，J＝6Hz，J＝5.5Hz，1H)，1.472(s，9H)，1.231-1.360(m，3H)，0.979-1.223(m.3H)，0.887-0.90(d，J＝6.5Hz，2H). 13CNMR(DMSO-d 6)：δ/ppm＝171.30，170.44，169.91，156.82，137.78，136.52，135.32，128.54，128.19，127.96，126.91，121.97，119.60，110.84，106.20，80.03，75.93，74.29，71.47，59.10，56.89，42.59，33.97，30.87，28.79，28.31，24.94，23.02，22.15.
Embodiment 43 Boc-Gln-1,2,3,4-Tetrahydrocarboline-3-acyl group-Gln-OBzl (7d)
According to the operation of preparation 7a, from 0.707g (1.60mmol) Boc-Gln-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.325g (30.68%) title compound (colorless solid).TLC (chloroform/methanol, 10: 1, Rf=0.2); Mp114-117 ℃; [α] D 25=16.7 (C=1.0, methyl alcohol); ESI-MS (m/z): 663.3 [M+H] +.IR (KBr): 3334,2940,2856,1750,1662,1627,1520,1450,1166,743,697. 1H NMR (300MHz, CDCl 3-d 6): δ/ppm=7.207-7.487 (m, 7H), 7.037-7.085 (m, 2H), 4.493 (m, 1H); 4.908-5.120 (m, 4H), 5.711-5.811 (m, 2H), 3.5825 (m; J=5.4Hz, 1H), 3.087 (dd, J=5.5Hz, J=15.5Hz; 1H), 2.190-2.400 (m, 8H), 1.4195 (s, 9H). 13CNMR (DMSO-d 6): δ/ppm=174.56,173.97,172.83,171.87,170.34,156.72,136.77,136.56; 130.19,128.80,128.36,128.12,127.96,126.84,121.26,118.90; 118.03,111.49,105.00,79.64,66.25,65.37,52.74,51.43; 31.68,31.04,29.44,28.67,27.62,26.79,23.04.
Embodiment 44 Boc-Leu-1,2,3,4-Tetrahydrocarboline-3-acyl group-Leu-OBzl (7e)
According to the operation of preparation 7a, from 0.387g (0.902mmol) Boc-Leu-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.252g (44.2%) title compound (colorless solid).TLC (sherwood oil/acetone, 3: 1, Rf=0.3); Mp81.9-83.2 ℃; [α] D 25=27.4 (C=1.0, methyl alcohol); ESI-MS (m/z): 633.6 [M+H] +.IR (KBr): 3313,2956,2931,1739,1680,1643,1521,1435,1165,744,697. 1H NMR (500MHz, DMSO-d 6): δ/ppm=7.233-7.710 (m, 7H), 7.084-7.1475 (m, 2H), 4.436-4.895 (m, 2H); 4.90-5.230 (m, 4H), 5.255-5.524 (m, 1H), 3.505 (m, J=15Hz; J=15.3Hz, 1H), 2.8558 (dd, J=4.5Hz, J=5.1Hz, 1H); 2.191-2.193 (m, 6H), 1.444 (s, 9H), 0.668-1.276 (m, 12H). 13CNMR (DMSO-d 6): δ/ppm=173.30,172.54,169.20,168.26,156.83,136.31,135.56; 128.64,128.57,128.32,127.86,121.90,119.58,110.83; 106.24,80.52,66.81,66.65,55.60,41.25,40.50; 30.88,28.44,23.33,22.83,21.91,21.38.
Embodiment 45 Boc-Phe-1,2,3,4-Tetrahydrocarboline-3-acyl group-Phe-OBzl (7f)
According to the operation of preparation 7a, from 0.744g (1.61mmol) Boc-Phe-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.520g (46.14%) title compound (colorless solid).TLC (sherwood oil/acetone, 3: 1, Rf=0.3); Mp94-97 ℃; [α] D 25=-10.9 (C=1.0, methyl alcohol); ESI-MS (m/z): 701.7 [M+H] +.IR (KBr): 3292,2952,2890,1735,1685,1642,1521,1454,1166,1030,742,697. 1H NMR (500MHz, CDCl 3-d 6): δ/ppm=7.171-7.323 (m, 17H), 7.017-7.091 (m, 2H), 4.652-4.754 (m, 2H); 4.759-4.986 (m, H), 4.990-5.107 (m, 1H), 5.129-5.202 (m, 2H); 5.134-5.410 (m, 1H), 2.894-3.502 (m, 6H), 1.4795 (s, 9H). 13CNMR (DMSO-d 6): δ/ppm=172.06,171.34,168.98,156.16,154.63,136.89,136.26,135.81; 129.63,128.96,128.66,127.92,126.96,126.65,122.40; 122.08,119.61,110.64,106.24,80.27,67.45,66.93; 53.48,52.44,38.77,37.59,36.81,28.56,21.13.
Embodiment 46 Boc-Ile-1,2,3,4-Tetrahydrocarboline-3-acyl group-Ile-OBzl (7g)
According to the operation of preparation 7a, from 0.551g (1.284mmol) Boc-Ile-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.541g (66.65%) title compound (colorless solid).TLC (sherwood oil/acetone, 3: 1, Rf=0.3); Mp 96-98 ℃; [α] D 25=-1.0 (C=1.0, methyl alcohol); ESI-MS (m/z): 633.6 [M+H] +.IR (KBr): 3315,2964,2856,1735,1680,1624,1521,1454,1431,1165,1020,743,699. 1H NMR (500MHz, DMSO-d 6): δ/ppm=7.488 (dd, J=8Hz, 1H), 7.258-7.467 (m, 6H), 7.151 (m, 1H), 7.1025 (t; J=7.5Hz, 1H), 4.436-5.239 (m, 7H), 3.4925 (m, J=9.3Hz, 1H); 2.958 (dd, J=5.7Hz, J=15HZ, 1H), 2.201 (s, 1H), 1.676 (s; 1H), 1.4395 (s, 9H), 1.067-1.399 (m, 4H), 0.756-0.973 (m, 12H). 13CNMR (DMSO-d 6): δ/ppm=173.29,172.85,169.07,156.22,155.45,136.41,135.29,128.59; 128.54,128.39,126.82,125.06,119.62,111.47,109.87,80.24; 67.19,66.96,55.90,52.19,38.78,37.92,36.53,28.33; 25.42,24.85,23.41,22.82,22.42,16.01,15.89.
Embodiment 47 Boc-Met-1,2,3,4-Tetrahydrocarboline-3-acyl group-Met-OBzl (7h)
According to the operation of preparation 7a, from 0.332g (0.743mmol) Boc-Met-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.090g (18.15%) title compound (colorless solid).TLC (sherwood oil/acetone, 3: 1, Rf=0.25); Mp 73-75 ℃; [α] D 25=-18.2 (C=1.0, methyl alcohol); ESI-MS (m/z): 691.4 [M+Na] +[591.1 M+Na-Boc] +.IR (KBr): 3315,2985,2917,1735,1691,1648,1526,1441,1167,1042,747,693. 1H NMR (500MHz, CDCl 3-d 6): δ/ppm=7.487 (dd, J=7.5Hz, J=8Hz, 1H), 7.251-390 (m, 6H), 7.054 (t, J=7.5Hz, 1H), 6.9815 (t, J=7.5Hz; 1H), 5.451 (m, 1H), 5.316 (dd, J=7Hz, J=5.5Hz, 1H), 5.006-5.164 (m, 3H), 4.8515 (m; 1H), 4.5725 (m, 1H), 3.3945 (dd, J=9.3Hz, J=9.5Hz, 1H), 2.976 (dd, J=4.5Hz, J=5.0Hz; 1H), 2.661 (t, J=7Hz, 1H), 2.5815 (t, J=6.5Hz, 1H), 2.413 (m, 1H), 2.2775 (t; J=7Hz, 1H), 2.136-2.200 (m, 4H), 1.997-2.100 (m, 2H), 1.889-1.967 (m, 4H), 1.3775 (s, 9H). 13CNMR (DMSO-d 6): δ/ppm=172.49,171.42,171.33,156.56,136.58,136.43,135.57; 128.65,128.60,128.36,127.86,122.73,119.68,110.96; 106.37,80.77,67.50,66.99,55.72,52.29,50.24; 31.70,30.88,29.77,28.33,22.64,15.63,15.26.
Embodiment 48 Boc-Tyr-1,2,3,4-Tetrahydrocarboline-3-acyl group-Tyr-OBzl (7i)
According to the operation of preparation 7a, from 0.586g (1.220mmol) Boc-Tyr-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.247g (27.66%) title compound (colorless solid).TLC (sherwood oil/acetone, 2: 1, Rf=0.25); Mp135-139 ℃; [α] D 25=1.1 (C=1.0, methyl alcohol); ESI-MS (m/z): 733.4 [M+H] +, 755.7 [M+Na] +.IR (KBr): 3398,2970,2855,1730,1690,1640,1520,1448,1228,1168,1020,744,699. 1H NMR (500MHz, CDCl 3-d 6): δ/ppm=7.310-7.790 (m, 7H), 6.620-7.206 (m, 10H), 5.955 (m, 1H), 5.586 (m, 1H), 4.955-5.360 (m, 3H), 4.410-4.80 (m, 2H), 3.215 (d, J=15Hz, 1H), 2.785-3.105 (m, 5H), 1.4045 (s, 9H). 13CNMR (DMSO-d 6): δ/ppm=173.39,171.69,168.94,155.88,155.35,136.11,135.60,130.57; 128.64,128.55,128.08,127.34,126.51,125.25,121.43; 118.97,115.77,110.90,105.94,80.81,67.09,56.20; 54.23,52.52,41.37,38.75,37.84,28.42,22.64.
Embodiment 49 Boc-Trp-1,2,3,4-Tetrahydrocarboline-3-acyl group-Trp-OBzl (7j)
According to the operation of preparation 7a, from 0.461g (0.918mmol) Boc-Trp-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.535g (74.9%) title compound (colorless solid).TLC (sherwood oil/acetone, 3: 1, Rf=0.25); Mp 128-130 ℃; [α] D 25=25.2 (C=1.0, methyl alcohol); ESI-MS (m/z): 801.9 [M+Na] +[701.5 M+Na-Boc] +.IR (KBr): 3404,3323,2956,2856,1735,1647,1624,1496,1456,1234,1163,1010,767,693. 1H NMR (500MHz, DMSO-d 6): δ/ppm=7.599 (dd, J=7.5Hz, J=5.4Hz, 1H), 6.877-7.510 (m, 18H), 5.1075 (d, J=17.1Hz, 1H), 4.360-5.098 (m, 6H), 3.590 (m, 1H), 2.950-3.395 (m, 4H), 2.892 (m, 1H), 1.3385 (s, 9H). 13CNMR (DMSO-d 6): δ/ppm=172.78,171.88,169.87,156.46,155.35,136.61,136.45,130.22; 129.61,128.72,128.08,127.89,127.57,124.54,123.97; 121.47,118.95,111.34,110.71,109.86,79.32,78.59; 66.28,55.22,54.53,41.82,38.58,28.69,21.69.
Embodiment 50 Boc-Val-1,2,3,4-Tetrahydrocarboline-3-acyl group-Val-OBzl (7k)
According to the operation of preparation 7a, from 0.550g (1.330mmol) Boc-Val-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.40g (43.8%) title compound (colorless solid).TLC (sherwood oil/acetone, 3: 1, Rf=0.3); Mp99.6-101 ℃; [α] D 25=-4.7 (C=1.0, methyl alcohol); ESI-MS (m/z): 627.5 [M+Na] +[527.5 M+Na-Boc] +.IR (KBr): 3327,2966,2933,1732,1678,1624,1500,1456,1367,1236,1166,1020,740,699. 1H NMR (500MHz, DMSO-d 6): δ/ppm=7.033-7.510 (m, 7H), 7.103 (t, J=8.5Hz, 1H), 6.9645 (t, J=7.5Hz; 1H), 5.510 (m, 1H), 5.215 (m, 1H), 4.876-5.098 (m, 3H); 4.420 (m, 1H), 4.151 (m, 1H), 3.395 (m, 1H), 2.987 (m; 1H), 2.212-2.052 (m, 2H), 1.366 (s, 9H), 0.793-0.943 (m, 12H). 13CNMR (DMSO-d 6): δ/ppm=173.19,172.81,170.58,156.46,156.14,136.69,130.54; 128.82,128.48,128.39,126.99,121.30,118.91,111.42; 104.74,78.91,66.29,58.51,57.64,56.65,39.18; 30.57,30.15,28.63,22.99,19.77,18.90.
Embodiment 51 Boc-Lys (Boc)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Lys (Z)-OBzl (7l)
According to the operation of preparation 7a, from 0.493g (0.906mmol) Boc-Lys (Boc)-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.408g (50.24%) title compound (colorless solid).TLC (oil mystery/acetone, 2: 1, Rf=0.3); Mp82.6-84.6 ℃; [α] D 25=1.3 (C=1.0, methyl alcohol); ESI-MS (m/z): 898.0 [M+H] +.IR (KBr): 3313,2974,2935,1735,1678,1643,1517,1456,1365,1248,1168,1040,742,697. 1H NMR (500MHz, DMSO-d 6): δ/ppm=7.210-7.580 (m, 12H), 7.010-7.198 (m, 2H), 5.048-5.298 (m, 6H); 4.899 (m, 1H), 4.398-4.750 (m, 2H), 3.502 (m, 1H); 3.026-3.310 (m, 4H), 2.958 (m, 1H), 1.650-1.910 (m, 4H); 1.522-1.610 (m, 4H), 1.448 (s, 18H), 0.8-1.391 (m, 4H). 13CNMR (DMSO-d 6): δ/ppm=172.92,171.91,169.94,156.57,156.21,155.77,136.64,135.16; 128.64,128.56,128.07,123.01,121.78,119.75,118.21,110.90; 80.35,67.36,66.84,66.32,55.83,52.42,42.22; 40.89,31.86,30.89,29.88,28.40,22.59,21.85.
Embodiment 52 Boc-Arg (NO2)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Arg (NO2)-OBzl (7m)
According to the operation of preparation 7a, from 1.14g (2.220mmol) Boc-Arg (NO 2)-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.770g (42.9%) title compound (yellow solid).TLC (chloroform/methanol, 10: 1, Rf=0.2); Mp131-133.2 ℃; [α] D 25=4.2 (C=1.0, methyl alcohol); ESI-MS (m/z): 809.3 [M+H] +.IR (KBr): 3304,2939,2856,1735,1624,1533,1445,1259,1161,740,693. 1H NMR (300MHz, DMSO-d 6): δ/ppm=7.137-7.405 (m, 7H), 7.0425 (t, J=7.8Hz, 1H), 6.9635 (m; 1H), and 4.610-5.810 (m, 5H), 4.12-4.528 (m, 2H), 3.3975 (q; J=7.2Hz, J=14.1Hz, 1H), 3.03-3.270 (m, 4H), 2.932 (m; 1H), 1.374-1.980 (m, 8H), 1.3675 (s, 9H). 13CNMR (DMSO-d 6): δ/ppm=172.93,172.42,170.24,159.8,156.61,155.94,136.74; 130.22,128.81,128.39,127.46,121.27,118.92,118.01; 111.45,105.06,79.17,66.33,65.36,52.86,51.42; 50.82,29.05,28.62,25.30,23.81,21.20.
Embodiment 53 Boc-Thr (Bzl)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Thr (Bzl)-OBzl (7n)
According to the operation of preparation 7a, from 0.777g (1.53mmol) Boc-Thr (Bzl)-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.416g (34.5%) title compound (colorless solid).TLC (sherwood oil/acetone, 3: 1, Rf=0.2); Mp184-186 ℃; [α] D 25=6.4 (C=1.0, methyl alcohol); ESI-MS (m/z): 811.8 [M+Na] +[711.6 M+Na-Boc] +.IR (KBr): 3305,2974,2856,1735,1678,1647,1525,1452,1286,1163,1104,736,697. 1H NMR (500MHz, CDCl 3-d 6): δ/ppm=7.160-7.387 (m, 17H), 7.045-7.092 (m, 2H), 4.767-5.128 (m, 9H), 4.466-4.667 (m; J=4.5Hz, 2H), 3.805-4.210 (m, 2H), 3.310 (m, 1H), 2.6335 (m; J=15.5Hz, 1H), 1.541 (s, 9H), 1.447-1.462 (m, 6H). 13CNMR (DMSO-d 6): δ/ppm=172.96,171.73,169.91,156.94,153.79,137.77,136.65,135.31; 129.33,128.81,128.73,128.20,127.96,126.71,123.96,121.83; 119.46,110.99,104.29,79.99,79.64,74.52,71.49,67.09; 66.89,59.93,33.89,28.80,24.99,23.61,22.63,16.12.
Embodiment 54 Boc-Ser (Bzl)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Ser (Bzl)-OBzl (7o)
According to the operation of preparation 7a, from 0.951g (1.93mmol) Boc-Ser (Bzl)-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.733g (49.97%) title compound (colorless solid).TLC (sherwood oil/acetone, 3: 1, Rf=0.3); Mp105-108 ℃; [α] D 25=6.5 (C=1.0, methyl alcohol); ESI-MS (m/z): 784.6 [M+Na] +[684.3 M+Na-Boc] +.IR (KBr): 3330,2985,2856,1736,1685,1620,1520,1452,1165,1110,744,693. 1H NMR (500MHz, CDCl 3-d 6): δ/ppm=7.236-7.528 (m, 17H), 7.086-7.111 (m, 2H), 5.5005 (dd, J=8Hz; J=6Hz, 1H), 4.899-5.327 (m, 4H), 4.54-4.890 (m, 2H); 4.265-4.50 (m, 4H), 3.587-3.930 (m, 4H), 3.433 (m, 1H); 2.828 (dd, J=4.5Hz, J=5Hz, 1H), 1.430 (s, 9H). 13CNMR (DMSO-d 6): δ/ppm=171.72,170.17,169.78,155.71,154.68,137.53,136.47,135.33,129.78; 128.52,128.33,128.13,128.00,127.91,127.83,127.65,122.70; 121.86,119.73,111.47,107.62,80.35,73.63,73.08,70.95; 69.72,69.25,67.88,53.04,52.83,38.98,28.79,22.59.
Embodiment 55 Boc-Cys (CH2-C6H4-OCH3)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Cys (But)-OBzl (7p)
According to the operation of preparation 7a, from 1.426g (2.65mmol) Boc-Cys (CH 2-C 6H 4-OCH 3)-1,2,3,4-Tetrahydrocarboline carboxylic acid obtains 0.687g (32.9%) title compound (colorless solid).TLC (sherwood oil/acetone, 3: 1, Rf=0.3); Mp72.3-74 ℃; [α] D 25=-14.7 (C=1.0, methyl alcohol); ESI-MS (m/z): 789.4 [M+H] +[811.6 M+Na] +.IR (KBr): 3330,2985,2857,1735,1685,1640,1526,1450,1256,1165,1040,743,693. 1H NMR (500MHz, DMSO-d 6): δ/ppm=7.317-7.450 (m, 7H), 7.098-7.288 (m, 5H), 6.992 (m, 1H), 5.149 (d, J=4Hz; 2H), 4.854 (m, 1H), 4.752 (m, 1H), 4.651 (m, 1H), 4.411-4.448 (m; 2H), 3.905 (s, 3H), 3.7735 (d, J=4.5Hz, 2H), 3.503 (m, 1H); 2.935-3.215 (m, 4H), 2.893 (m, 1H), 1.474 (s, 9H), 1.1945 (m, 9H). 13CNMR (DMSO-d 6): δ/ppm=172.23,171.53,170.03,168.78,158.42,154.89,136.56,130.73,130.15; 128.55,128.12,127.22,126.70,122.10,121.92,119.64,114.43; 110.89,107.25,80.14,67.37,67.15,55.81,55.29,55.23; 50.49,42.66,36.25,34.54,33.96,28.33,24.94,21.41.
Embodiment 56 Boc-Asp (OBzl)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Asp (OBzl)-OBzL (7q)
According to the operation of preparation 7a, from 0.588g (1.074mmol) 1,2,3,4-Tetrahydrocarboline-3-acyl group-Asp (OBzl)-OBzl obtains 0.385g (43.93%) title compound (colorless solid).TLC (sherwood oil/acetone, 2: 1, Rf=0.3); Mp62-65 ℃; [α] D 25=4.5 (C=1.0, methyl alcohol); ESI-MS (m/z): 817.5 [M+H] +.IR (KBr): 3331,2986,2855,1735,1685,1620,1521,1452,1160,1010,744,697. 1H NMR (500MHz, DMSO-d 6): δ/ppm=7.115-7.450 (m, 17H), 7.106 (m, 1H), 7.0895 (m, J=8.5Hz; 1H), 5.610 (m, 1H), 5.007-5.410 (m, 8H), 4.820 (d; J=12.5Hz, 1H), 4.630 (m, 1H), 3.725 (m, 1H); 2.842-3.305 (m, 4H), 2.645 (m, 1H), 1.401 (s, 9H). 13CNMR (DMSO-d 6): δ/ppm=172.12,171.86,170.71,170.19,169.96,154.89,136.52; 135.47,129.55,128.78,128.52,128.30,127.98,122.72; 122.10,119.65,111.46,107.54,80.72,67.67,66.24; 49.44,48.96,41.97,37.96,36.44,28.24,22.41.
Embodiment 57 Boc-Glu (OBzl)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Glu (OBzl)-OBzL (7r)
According to the operation of preparation 7a, from 0.465g (1.38mmol) 1,2,3,4-Tetrahydrocarboline-3-acyl group-Glu (OBzl)-OBzl obtains 0.323g (36.13%) title compound (colorless solid).TLC (sherwood oil/acetone, 2: 1, Rf=0.3); Mp156-158 ℃; [α] D 2 5=14.9 (C=1.0, methyl alcohol); ESI-MS (m/z): 845.2 [M+H] +.IR (KBr): 3320,3200,1724,1680,1630,1520,1452,1230,1168,744,693. 1H NMR (500MHz, DMSO-d 6): δ/ppm=7.230-7.502 (m, 17H), 7.092-7.1165 (m, 2H), 5.215-5.610 (m, 2H); 5.110-5.205 (m, 2H), 4.995-5.055 (m, 5H), 5.714 (m, 1H); 5.510 (m, 1H), 3.510 (m, 1H), 2.899 (m; 1H), 2.087-2.634 (m, 8H), 1.4105 (m, 9H). 13CNMR (DMSO-d 6): δ/ppm=171.72,170.17,169.78,155.71,154.68,137.53,136.47,135.33,129.78; 128.52,128.33,128.13,128.00,127.91,127.83,127.65,122.70; 121.86,119.73,111.47,107.62,80.35,73.63,73.08,70.95; 69.72,69.25,67.88,53.04,52.83,38.98,28.99,22.59.
Embodiment 58 HClNH2Ala-1,2,3,4-Tetrahydrocarboline-3-acyl group-Ala-OBzl (8a)
0.10g Boc-Ala-KLSS-Ala-OBzl (0.18mmol) is dissolved in the 2ml ETHYLE ACETATE, adds hydrogenchloride-ethyl acetate solution of 1ml again in the solution that obtains.TLC (oil mystery/acetone, 3: 1, Rf=0.3) detect, raw material point disappearance stopped reaction, drain solvent after, add the 10ml ether and drain, repeat 3 times after adding 10ml ether ground and filtered 0.085g (96.14%) title compound (yellow solid).M.p.:146-148 ℃; [α] D 25=1.4 (C=1.0, methyl alcohol); ESI-MS (m/z): 449.5 [M+H] +. 1H NMR (500MHz, DMSO-d 6): δ/ppm=10.99 (m, 1H), 8.75 (m, 1H), 8.40 (m, 2H), 7.75-7.50 (m, 7H), 7.05 (m; 1H), 6.95 (m, 1H), 5.65 (m, J=5Hz, 1H), 5.15 (m, 1H), 4.85-5.05 (m; 2H), 4.65 (m, 1H), 4.30 (m, 1H), 3.70 (m, 1H), 3.35 (m, J=10Hz; 1H), 3.05 (m, J=5Hz, 1H), 1.45-1.50 (m, 3H), 1.30-1.38 (m, 3H). 13CNMR (DMSO-d 6): δ/ppm=172.48,170.75,169.76,136.79,136.30,130.18,129.67,128.78; 128.11,126.88,121.41,119.15,118.01,111.62,104.48,67.42; 66.29,50.92,47.98,33.80,28.64,21.54,17.42.
Embodiment 59 HClNH2Gly-1,2,3,4-Tetrahydrocarboline-3-acyl group-Gly-OBzl (8b)
According to the operation of preparation 8a, from 0.089g (0.17mmol) Boc-Gly-1,2,3,4-Tetrahydrocarboline-3-acyl group-Gly-OBzl obtains 0.077g (97.8%) title compound (yellow solid).Mp 148-151 ℃; [α] D 25=52.8 (C=1.0, methyl alcohol); ESI-MS (m/z): 421.4 [M+H] +. 1H NMR (500MHz, DMSO-d 6): δ/ppm=11.120 (s, 1H), 8.75 (m, J=9.5Hz, 1H), 8.35 (s, 2H), 7.21-7.51 (m; 7H), 7.05 (t, J=11.5Hz, 1H), 6.95 (t, J=15.5Hz, 1H), 5.68 (m; J=9.5Hz, 1H), 5.05 (m, 2H), 4.85 (s, 1H), 4.05-4.51 (m, 2H); 3.75-3.98 (m, 3H), 3.45 (m, J=11.5Hz, 1H), 2.98 (m, J=10.5Hz, 1H). 13CNMR (DMSO-d 6): δ/ppm=172.45,170.28,167.76,136.77,136.29,129.87,129.36,128.66,128.35,126.76,121.45,118.97,118.04,111.55,105.14,66.38,54.46,51.38,23.27,21.56.
Embodiment 60 HClNH2Pro-1,2,3,4-Tetrahydrocarboline-3-acyl group-Pro-OBzl (8c)
According to the operation of preparation 8a, from 0.13g (0.22mmol) Boc-Pro-1,2,3,4-Tetrahydrocarboline-3-acyl group-Pro-OBzl obtains 0.110g (94.63%) title compound (yellow solid).Mp 113-115 ℃; [α] D 25=-61.4 (C=1.0, methyl alcohol); ESI-MS (m/z): 501.4 [M+H] +. 1HNMR (500MHz, DMSO-d 6): δ/ppm=10.45 (m, 1H), 8.56 (s, 1H), 7.21-7.46 (m, 7H), 7.05 (t, 1H); 6.98 (t, J=10Hz, 1H), 5.55 (m, 1H), 5.15 (m, 1H); 4.15-4.95 (m, 2H), 4.18-4.52 (m, 2H), 4.05 (m, 1H), 3.60-3.85 (m; 2H), 2.89-3.35 (m, 4H), 2.25 (m, 1H), 1.5-2.05 (m, 7H). 13CNMR (DMSO-d 6): δ/ppm=171.81,169.77,169.10,136.74,136.25,129.53,129.34; 128.97,128.15,126.72,121.76,118.98,118.01,111.64; 104.05,67.73,66.20,59.15,58.94,47.97,42.18; 33.80,29.58,28.21,25.29,24.91,21.98.
Embodiment 61 HClNH2Gln-1,2,3,4-Tetrahydrocarboline-3-acyl group-Gln-OBzl (8d)
According to the operation of preparation 8a, from 0.08g (0.12mmol) Boc-Gln-1,2,3,4-Tetrahydrocarboline-3-acyl group-Gln-OBzl obtains 0.072g (98.92%) title compound (yellow solid).Mp 147-149 ℃; [α] D 25=14.3 (C=1.0, methyl alcohol); ESI-MS (m/z): 563.4 [M+H] +. 1HNMR (500MHz, DMSO-d 6): δ/ppm=10.99 (d, J=10Hz, 1H), 8.75 (m, J=10Hz, 1H), 8.45-8.55 (m, 4H), 7.15-7.52 (m, 7H); 7.05 (t, J=10Hz, 1H), 6.89 (t, J=5Hz, 1H), 5.65 (m, J=5Hz, 1H); 5.15 (m, J=15Hz, 1H), 4.75-4.92 (m, 2H), 4.45-4.65 (m, 2H), 4.20 (m, 1H); 3.38 (m, J=10Hz, J=5Hz, 1H), 3.05 (m, J=5Hz, 1H), 2.05-2.30 (m, 8H). 13CNMR (DMSO-d 6): δ/ppm=174.13,172.40,171.78,170.96,169.97,136.80,136.31; 130.10,129.60,128.79,128.15,126.87,121.40,118.95; 117.92,111.92,104.71,66.31,54.20,52.71,50.09; 31.88,31.65,30.43,30.04,26.69,21.54.
Embodiment 62 HClNH2Leu-1,2,3,4-Tetrahydrocarboline-3-acyl group-Leu-OBzl (8e)
According to the operation of preparation 8a, from 0.155g (0.245mmol) Boc-Leu-1,2,3,4-Tetrahydrocarboline-3-acyl group-Leu-OBzl obtains 0.131g (93.95%) title compound (yellow solid).Mp 101-103 ℃; [α] D 25=28.9 (C=1.0, methyl alcohol); ESI-MS (m/z): 533.5 [M+H] +. 1HNMR (500MHz, DMSO-d 6): δ/ppm=11.05 (m, 1H), 8.30-8.89 (m, 3H), 7.16-7.37 (m, 7H), 6.89-7.09 (m, J=5Hz; 2H), 5.65 (m, J=5Hz, 1H), 4.95-5.15 (m, 2H), 4.85 (m, J=10Hz; 1H), 4.65 (m, 1H), 4.33 (m, 1H), 4.05 (m, 1H), 3.46 (m; 1H), 2.95 (m, 1H), 1.25-1.71 (m, 6H), 0.57-0.99 (m, 12H). 13CNMR (DMSO-d 6): δ/ppm=172.72,172.38,170.60,136.80,136.20,129.88,128.95; 128.77,128.30,126.64,121.30,118.97,117.97,111.40; 104.67,66.47,51.65,51.06,50.80,49.45,42.30; 33.80,28.64,25.81,24.90,24.64,22.03,21.53.
Embodiment 63 HClNH2Phe-1,2,3,4-Tetrahydrocarboline-3-acyl group-Phe-OBzl (8f)
According to the operation of preparation 8a, from 0.12g (0.17mmol) Boc-Phe-1,2,3,4-Tetrahydrocarboline-3-acyl group-Phe-OBzl obtains 0.108g (99.44%) title compound (yellow solid).Mp 122-124 ℃; [α] D 25=10.5 (C=1.0, methyl alcohol); ESI-MS (m/z): 601.4 [M+H] +. 1HNMR (500MHz, DMSO-d 6): δ/ppm=11.01 (m, 1H), 8.25-8.81 (m, 3H), 7.16-7.44 (m, 17H), 6.88-7.10 (m; 2H), 5.67 (m, 1H), 5.21 (m, J=5Hz, 1H); 5.05 (m, J=5Hz, 1H), 4.89-5.01 (m, 2H), 4.68 (m; J=15Hz, 1H), 3.81 (m, 1H), 2.89-3.36 (m, 6H). 13CNMR (DMSO-d 6): δ/ppm=172.70,171.37,169.90,137.75,136.20,136.12,130.36,129.89; 129.70,129.06,128.89,128.80,129.68,128.21,127.78,127.00; 126.86,126.76,121.30,118.88,117.94,111.45,104.35,66.62; 66.52,65.36,54.70,54.37,36.74,36.61,21.53.
Embodiment 64 HClNH2-Ile-1,2,3,4-Tetrahydrocarboline-3-acyl group-Ile-OBzl (8g)
According to the operation of preparation 8a, from 0.12g (0.19mmol) Boc-Ile-1,2,3,4-Tetrahydrocarboline-3-acyl group-Ile-OBzl obtains 0.105g (97.28%) title compound (yellow solid).Mp 94-96 ℃; [α] D 25=-0.8 (C=1.0, methyl alcohol); ESI-MS (m/z): 533.5 [M+H] +. 1HNMR (500MHz, DMSO-d 6): δ/ppm=11.00 (m, 1H), 8.70 (m, 1H), 8.20-8.45 (m, 2H), 7.15-7.54 (m, 7H); 6.89-7.12 (m, J=10Hz, 2H), 5.87 (m, J=5Hz, 1H), 5.01-5.29 (m, J=10Hz; 2H), and 4.81-5.00 (m, J=15Hz, 2H), 4.15-4.4 (m, J=5Hz, 2H), 2.89-3.45 (m; J=15Hz, 3H), 2.05 (m, 1H), 1.25-1.40 (m, 4H), 0.75-0.98 (m, 12H). 13CNMR (DMSO-d 6): δ/ppm=172.36,171.42,169.76,136.76,136.18,129.97,128.95,128.90; 128.37,126.70,121.40,119.02,117.83,111.61,104.24; 66.43,57.11,55.00,50.76,36.90,36.63,36.01; 28.63,25.42,25.03,23.73,21.25,15.59,11.75.
Embodiment 65 HClNH2-Met-1,2,3,4-Tetrahydrocarboline-3-acyl group-Met-OBzl (8h)
According to the operation of preparation 8a, from 0.10g (0.15mmol) Boc-Met-1,2,3,4-Tetrahydrocarboline-3-acyl group-Met-OBzl obtains 0.089g (98.91%) title compound (yellow solid).Mp 103-105 ℃; [α] D 25=-7.5 (C=1.0, methyl alcohol); ESI-MS (m/z): 569.4 [M+H] +. 1HNMR (500MHz, DMSO-d 6): δ/ppm=11.00 (m, 1H), 8.40-8.99 (m, 3H), 7.16-7.44 (m, 7H), 6.97-7.05 (m, J=5Hz, 1H), 7.08-7.11 (m; 1H), 5.47 (m, J=10Hz, 1H), 5.17 (m, 1H), 4.82-5.05 (m, 2H), 4.63 (m, J=5Hz; 1H), 4.38 (m, 1H), 3.58 (m, 1H), 3.35 (m, 1H), 3.05 (m, J=5Hz, 1H); 2.58-2.80 (m, 2H), 2.26-2.48 (m, 2H), 2.11-2.20 (m, 2H), 2.03-2.09 (m, 2H), 1.84-2.02 (m, 6H). 13CNMR (DMSO-d 6): δ/ppm=171.61,171.15,169.92,136.80,136.22,130.10,129.54; 128.88,128.21,126.85,121.46,119.04,118.04,111.62; 104.48,67.66,66.40,54.33,51.24,33.80; 30.84,30.35,30.13,29.92,23.92,14.99.
Embodiment 66 HClNH2-Tyr-1,2,3,4-Tetrahydrocarboline-3-acyl group-Tyr-OBzl (8i)
According to the operation of preparation 8a, from 0.15g (0.205mmol) Boc-Tyr-1,2,3,4-Tetrahydrocarboline-3-acyl group-Tyr-OBzl obtains 0.134g (97.67%) title compound (yellow solid).Mp 157-159 ℃; [α] D 25=8.1 (C=1.0, methyl alcohol); ESI-MS (m/z): 633.5 [M+H] +. 1HNMR (500MHz, DMSO-d 6): δ/ppm=10.96 (m, 1H), 9.45 (m, 2H), 8.25-8.65 (m, 3H), 7.25-7.45 (m; 5H), and 7.11-7.25 (m, 3H), 6.89-7.10 (m, 5H), 6.65-6.78 (m, 4H); 5.69 (m, J=10Hz, 1H), 5.05 (m, 1H), 4.45-4.95 (m, 3H); 4.21-4.35 (m, 2H), 3.30 (m, J=15Hz, 1H), 2.89-3.15 (m, 5H). 13CNMR (DMSO-d 6): δ/ppm=172.40,171.48,169.85,157.30,156.56,136.74,136.53; 131.24,130.48,129.83,128.76,127.54,126.76,124.67; 121.42,119.00,115.92,115.70,111.61,104.41,66.39; 60.21,55.01,54.65,42.04,36.18,24.09,21.53.
Embodiment 67 HClNH2-Trp-1,2,3,4-Tetrahydrocarboline-3-acyl group-Trp-OBZl (8j)
According to the operation of preparation 8a, from 0.07g (0.0899mmol) Boc-Trp-1,2,3,4-Tetrahydrocarboline-3-acyl group-Trp-OBzl obtains 0.064g (98.77%) title compound (brown solid).Mp 160-162 ℃; [α] D 25=45.0 (C=1.0, methyl alcohol); ESI-MS (m/z): 679.5 [M+H] +. 1H NMR (500MHz, DMSO-d 6): δ/ppm=10.89-11.15 (m, 3H), 8.52-8.79 (m, 2H), 8.25 (s, 1H), 7.15-7.57 (m, 10H); 6.89-7.11 (m, 9H), 5.12 (m, 1H), 4.99 (m, 1H), 4.67-4.89 (m; 2H), 4.25-4.62 (m, 2H), 3.40 (m, 1H), 2.89-3.35 (m, 6H). 13CNMR (DMSO-d 6): δ/ppm=172.44,171.43,169.97,136.80,136.74,136.10,130.02; 129.80,128.85,128.11,127.53,126.73,121.57,119.02; 118.34,112.05,111.45,109.60,104.39,66.36,60.22; 54.49,50.91,41.91,27.65,26.22,21.23.
Embodiment 68 HClNH2-Val-1,2,3,4-Tetrahydrocarboline-3-acyl group-Val-OBzl (8k)
According to the operation of preparation 8a, from 0.15g (0.25mmol) Boc-Val-1,2,3,4-Tetrahydrocarboline-3-acyl group-Val-OBzl obtains 0.030g (96.96%) title compound (yellow solid).Mp131-133 ℃; [α] D 25=-1.7 (C=1.0, methyl alcohol); ESI-MS (m/z): 505.5 [M+H] +. 1H NMR (500MHz, DMSO-d 6): δ/ppm=11.02 (m, 1H), 8.30-8.44 (m, 3H), 7.15-7.35 (m, 7H), 6.89-7.08 (m, J=5Hz, 2H); 5.68 (m, J=10Hz, 1H), 5.14 (m, J=5Hz.J=10Hz, 1H), 4.84-5.01 (m, 3H), 4.61 (m; 1H), 4.15 (m, J=5Hz, 1H), 3.85 (m, 1H), 3.16-3.33 (m, J=15Hz; 1H), 3.05-3.15 (m, J=10Hz, 1H), 2.15 (m, 1H), 0.81-1.19 (m, 12H). 13CNMR (DMSO-d 6): δ/ppm=171.63,171.40,169.70,136.76,136.21,130.45,129.96,128.79,128.47; 126.85,121.39,119.02,117.91,111.63,104.24,66.45,66.32; 58.03,50.75,30.58,30.17,29.88,24.42,19.05,17.35.
Embodiment 69 HClNH2-Lys-1,2,3,4-Tetrahydrocarboline-3-acyl group-Lys (Z)-OBzl (8l)
According to the operation of preparation 8a, from 0.10g (0.11mmol) Boc-Lys (Boc)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Lys (Z)-OBzl obtains 0.084g (97.86%) title compound (yellow solid).Mp118-120 ℃; [α] D 25=7.9 (C=1.0, methyl alcohol); ESI-MS (m/z): 697.6 [M+H] +. 1H NMR (500MHz, DMSO-d 6): δ/ppm=11.0485 (m, 1H), 8.35-8.75 (m, 3H), 8.05-8.25 (m, 3H), 7.15-7.51 (m, 12H), 7.05 (t; J=12Hz, 1H), 6.98 (t, J=12.5Hz, 1H), 5.56 (m, J=8.3Hz, 1H), 5.15 (m; 1H), 5.0 (s, 2H), 4.73-4.95 (m, 2H), 4.51 (m, 1H), 4.15 (m, 1H); 3.35 (m, 1H), 2.72-3.15 (m, 6H), 1.55-1.85 (m, 6H), 1.15-1.45 (m, 6H). 13CNMR (DMSO-d 6): δ/ppm=172.357,171.235,170.020,156.551,137.767,136.244,130.243,129.722; 128.937,128.147,126.668,121.394,118.967,117.869,111.584,104.334; 66.389,65.593,53.883,52.907,51.036,50.616,42.213,38.699; 38.373,30.909,30.597,29.422,26.796,23.184,21.159.
Embodiment 70 HClNH2-Arg (NO2)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Arg (NO2)-OBzl (8m)
According to the operation of preparation 8a, from 0.12g (0.148mmol) Boc-Arg (NO 2)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Arg (NO 2)-OBzl obtains 0.110g (99.48%) title compound (yellow solid).Mp163-165 ℃; [α] D 25=5.4 (C=1.0, methyl alcohol); ESI-MS (m/z): 709.5 [M+H] +. 1H NMR (500MHz, DMSO-d 6): δ/ppm=10.93 (m, 1H), 7.89-8.65 (m, 7H), 7.25-7.51 (m, 7H), 7.05 (t; J=5Hz, 1H), 6.89 (t, J=10Hz, J=5HZ, 1H); 5.53-5.83 (m, 2H), 4.85-5.25 (m, 3H), 4.35 (m, 1H); 3.05-3.45 (m, 7H), 1.92 (s, 2H), 1.5-1.85 (m, 8H). 13CNMR (DMSO-d 6): δ/ppm=172.36,171.73,170.13,159.79,136.76,136.19,130.13; 129.67,128.18,127.55,126.67,121.30,118.96,118.02; 111.60,104.43,66.38,60.19,54.05,52.63; 33.74,28.66,27.49,25.26,24.29,21.51.
Embodiment 71 HClNH2-Thr (Bzl)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Thr (Bzl)-OBzl (8n)
According to the operation of preparation 8a, from 0.15g (0.19mmol) Boc-Thr (Bzl)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Thr (Bzl)-OBzl obtains 0.130g (94.26%) title compound (yellow solid).Mp 98-100 ℃; [α] D 25=-7.1 (C=1.0, methyl alcohol); ESI-MS (m/z): 689.6 [M+H] +. 1H NMR (500MHz, DMSO-d 6): δ/ppm=11.00 (m, 1H), 8.78 (m, 1H), 8.23-8.56 (m, 2H), 7.15-7.409 (m, 17H); 6.89-7.11 (m, J=13Hz, 1H), 5.68 (m, J=12Hz, 1H), 4.88-5.25 (m; 3H), 4.21-4.80 (m, 8H), 4.15 (m, J=5Hz, 1H), 3.35 (m; J=12.5Hz, 1H), 3.05 (m, J=13Hz, 1H), 1.05-1.45 (m, 6H). 13CNMR (DMSO-d 6): δ/ppm=171.83,170.30,168.39,138.57,136.14,136.01,129.77,128.87; 128.76,128.50,128.47,128.34,128.00,127.89,126.71,123.37; 119.87,119.01,112.61,109.10,74.50,72.14,70.74,70.62; 66.88,64.91,63.04,57.02,33.79,25.82,16.99,16.70.
Embodiment 72 HCl-NH2-Ser (Bzl)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Ser (Bzl)-OBzl (8o)
According to the operation of preparation 8a, from 0.15g (0.1974mmol) Boc-Ser (Bzl)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Ser (Bzl)-OBzl obtains 0.136g (98.93%) title compound (yellow solid).Mp136-138 ℃; [α] D 25=-3.6 (C=1.0, methyl alcohol); ESI-MS (m/z): 661.5 [M+H] +. 1H NMR (500MHz, DMSO-d 6): δ/ppm=11.00 (m, 1H), 8.45-8.98 (m, 3H), 7.165-7.42 (m, 17H), 7.55 (m, J=10Hz; 1H), 6.99 (m, J=5Hz, 1H), 5.56 (m, J=5Hz, 1H); 5.23 (m, 1H), 4.89-5.04 (m, 2H), 4.25-4.89 (m, 6H), 3.48-3.91 (m; 5H), 3.35 (m, J=20Hz, 1H), 2.99 (m, J=5Hz, 1H). 13CNMR (DMSO-d 6): 171.07,170.27,167.83,138.22,137.95,137.69,136.50,130.09; 129.64,128.74,128.59,128.40,128.14,126.89,121.43; 119.00,117.96,111.62,104.46,72.86,72.73,69.47; 67.98,67.43,66.54,53.77,51.21,28.21,24.24.
Embodiment 73 HClNH2-Cys (CH2-C6H4-OCH3)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Cys (But)-OBzl (8p)
According to the operation of preparation 8a, from 0.15g (0.19mmol) Boc-Cys (CH 2-C 6H 4-OCH 3)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Cys (But)-OBzl obtains 0.136g (98.62%) title compound (yellow solid).Mp1132-134 ℃; [α] D 25=-12.2 (C=1.0, methyl alcohol); ESI-MS (m/z): 689.5 [M+H] +. 1H NMR (500MHz, DMSO-d 6): δ/ppm=10.99 (m, 1H), 8.45-8.95 (m, 3H), 7.15-7.47 (m, 9H), 6.55-7.15 (m; 4H), 5.35 (m, J=5Hz, 1H), 4.85-5.15 (m, 3H), 4.65 (m; 1H), 4.35 (m, J=5Hz, J=10Hz, 1H), 3.84 (m, 1H); 3.58-3.78 (m, 5H), 2.75-3.35 (m, 6H), 1.10-1.28 (m, 9H). 13CNMR (DMSO-d 6): δ/ppm=170.49,169.54,169.11,158.89,136.84,136.23,130.77,129.80; 129.55,128.80,128.19,126.92,121.44,118.97,117.92,114.41; 111.63,104.69,66.67,66.61,55.56,55.45,53.98; 49.75,42.64,35.59,31.81,31.10,30.94,21.53.
Embodiment 74 HClNH2-Asp (OBzl)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Asp (OBzl)-OBzl (8q)
According to the operation of preparation 8a, from 0.15g (0.184mmol) Boc-Asp (OBzl)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Asp (OBzl)-OBzl obtains 0.137g (99.04%) title compound (yellow solid).Mp 90-92 ℃; [α] D 25=-6.2 (C=1.0, methyl alcohol); ESI-MS (m/z): 717.5 [M+H] +. 1H NMR (500MHz, DMSO-d 6): δ/ppm=10.98 (m, 1H), 8.35-8.39 (m, 3H), 7.11-7.573 (m, 17H), 7.05 (t, J=11.5Hz; 1H), 6.99 (t, J=12Hz, 1H), 5.565 (m, J=9.5Hz, 1H); 5.05-5.21 (m, 4H), 4.83-5.00 (m, 4H), 4.65 (m, J=11Hz, 1H); 4.35 (m, 1H), 3.45 (m, J=25Hz, 1H), 2.67-3.25 (m, 5H). 13CNMR (DMSO-d 6): δ/ppm=172.40,171.48,169.85,157.30,156.56,136.74,136.53; 131.24,130.48,129.83,128.76,127.54,126.76,124.67; 121.42,119.00,115.92,115.70,111.61,104.41,66.39; 60.21,55.01,54.65,42.04,36.18,24.09,21.53.
Embodiment 75 HClNH2-Glu (OBzl)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Glu (OBzl)-OBzl (8r)
According to the operation of preparation 8a, from 0.20g (0.24mmol) Boc-Glu (OBzl)-1,2,3,4-Tetrahydrocarboline-3-acyl group-Glu (OBzl)-OBzl obtains 0.180g (97.32%) title compound (yellow solid).Mp76-78 ℃; [α] D 25=7.5 (C=1.0, methyl alcohol); ESI-MS (m/z): 745.5 [M+H] +. 1H NMR (500MHz, DMSO-d 6): δ/ppm=10.94 (m, 1H), 8.35-8.90 (m, 3H), 7.15-7.40 (m, 17H), 6.88-7.08 (m, 2H); 5.56 (m, J=5Hz, 1H), 4.89-5.25 (m, 6H), 4.85 (m, 1H), 4.61 (m; 1H), 4.25 (m, 1H), 3.65 (m, 1H), 3.38 (m, J=10Hz, 1H); 3.05 (m, J=10Hz, 1H), 2.55-2.79 (m, 6H), 1.81-2.46 (m, 2H). 13CNMR (DMSO-d 6): δ/ppm=172.54,172.33,171.46,171.06,169.89,136.85,136.27,130.07; 129.53,128.88,128.44,126.88,121.47,119.05,118.05,111.64; 104.54,66.55,54.32,52.34,50.09,42.08,30.55; 30.36,30.21,29.08,26.44,26.00,25.55,23.83.
Experimental example 1 The compounds of this invention anti-tumor in vivo activity experiment
1) experiment material
The compound 8a-r that test-compound: embodiment of the invention 58-75 is prepared;
Positive reference substance is a cytosine arabinoside
Laboratory animal: the ICR mouse, male, body weight 20+2g (± s); Provide by experimentation on animals center, Department Of Medicine, Peking University.One group of per 10 mouse, each one group of blank and positive control.
The knurl source: mouse S180 sarcoma, provide by experimentation on animals center, Department Of Medicine, Peking University, go down to posterity voluntarily and keep.
Solvent: 0.5%CMC-Na solution.
2) experimental technique
1. dosage setting
Test-compound 8a-r and positive control are made as 8.9 μ mol/kg, all adopt the abdominal cavity single-dose.
2. medicine preparation
Test-compound 8a-r indissoluble in water adds the wetting hydrotropy of a spot of tween 80 during experiment, add 0.5%CMC-Na solution to required concentration gradually and get final product.The positive reference substance cytosine arabinoside is water-soluble, adopts the 0.5%CMC-Na dissolving to get final product.
3) dosage and dosage regimen
Test-compound 8a-r is all with the abdominal cavity single-dose.By corresponding dosage once a day, the 0.2ml/ mouse, successive administration 7 days, administration is 7 times altogether.
Negative control is with isopyknic corresponding solution, all with intraperitoneal administration.By corresponding dosage once a day, the 0.2ml/ mouse, successive administration 7 days, administration is 7 times altogether.
The positive reference substance cytosine arabinoside is by the dosage of 8.9 μ mol/kg, intraperitoneal administration.Once a day, the 0.2ml/ mouse, successive administration 7 days, administration is 7 times altogether.
4) foundation of animal model
Adopt anti-tumor in vivo armpit subcutaneous vaccination model: under aseptic condition, extract inoculation and get the vigorous S180 ascitic tumor knurl liquid of growth after 5 days; Be diluted to the liquid thorough mixing of (1: 2) with saline water, the tumour cell suspension is calculated cell concn and cell survival rate with freshly prepared substratum dilution counting by following formula.
Viable count/4 * 10 in the big grid in cell concn=4 4* extension rate=cell count/ml
Cell survival rate=viable count/(viable count+dead cell number) * 100%
Survival rate is prepared into 1 * 10 greater than 90% knurl liquid with the homogenate method 7The cell suspension of individual/ml in corresponding host's armpit subcutaneous vaccination 0.2ml/ mouse, is processed the solid tumor animal model.
5) detect index and method
Neurotoxicity is observed in a body
Observe autonomic activities, the mental status, hair, breathing, the diet of the reaction mouse of each treated animal of administration every day, the ight soil proterties.
The mensuration of b solid tumor tumour inhibiting rate and body weight gain
After each organizes successive administration 7d, take off cervical vertebra in 8d and put to death mouse, take by weighing body weight (execution body weight), with the fixing right armpit tumor location of mouse of tweezers, cut off skin then, expose tumour, blunt separation is weighed, by following formula calculating tumour inhibiting rate.
Tumour inhibiting rate %=[(it is heavy that the average knurl of negative control group weighs the average knurl of an administration group)/average knurl of negative control group is heavy] * 100%
Body weight gain (g)=execution body weight-original body weight-knurl is heavy
The c statistical method
This experimental data statistics all adopts t check and variance analysis, with (x ± SD) expression.
6) experimental result
Compound 8a-r lists table 1 in to the tumour inhibiting rate of S180 tumor-bearing mice and the influence of body weight.
Table 1 compound 8a-r is to the tumour inhibiting rate of S180 tumor-bearing mice and the influence of body weight a
Group Tumour inhibiting rate % Knurl heavy (g) Weight increase (g)
NS 0 1.47±0.39 8.56±2.37
Arc 49.49±4.38 c 0.78±0.22 c 8.13±1.83
8a 54.24±8.4 c 0.60±0.03 c 8.38±1.49
8b 26.54±9.24 1.08±0.37 9.60±2.93
8c 15.21±9.04 1.22±0.24 7.24±3.89
8d 31.56±5.56 b 1.01±0.26 b 8.69±2.64
8e 48.99±4.46 c 0.72±0.24 c 9.08±1.54
8f 61.68±5.81 e 0.54±0.08 e 10.94±2.82
8g 75.12±7.76 f 0.38±0.21 f 2.53±3.92 b
8h 45.8±4.66 c 0.70±0.17 c 9.96±1.64
8i 57.41±5.48 d 0.62±0.15 d 0.05±2.72 d
8j 30.76±9.42 1.08±0.38 8.31±1.50
8k 27.65±10.91 1.15±0.42 8.74±2.58
8l 22.57±7.02 1.13±0.27 8.31±4.13
8m 49.84±11.59 c 0.67±0.29 c 8.71±2.47
8n 53.58±4.35 d 0.69±0.21 d 8.56±3.92
8o 27.59±12.24 1.08±0.41 6.82±2.94
8p 43.04±9.46 b 0.86±0.34 b 8.15±3.28
8q 25.26±10.21 b 1.07±0.18 b 8.65±2.69
8r 16.68±8.34 1.21±0.29 7.93±2.57
A) Arc (cytosine arabinoside) and 8a-r dosage are 8.9 μ mol/kg, NS=saline water, and n=10, knurl weighs and weight increase is expressed as x ± SDg; Inhibiting rate is expressed as x ± SD%; After the administration each treated animal do not observe occur the trembling of bibliographical information, jump, tic, tetanic, lie on the back, the symptom of accelerated breathing; B) compare p＜0.05 with NS; C) compare p＜0.01 with NS; D) compare p＜0.001 with NS; E) compare p＜0.05 with cytosine arabinoside; F) compare p＜0.05. with cytosine arabinoside
Experimental result shows that The compounds of this invention has definite anti-tumor activity.
According to the result of test of significance, the compound 8f and the 8g that choose p＜0.001 carry out dose-effect relationship research, and the result is referring to table 2.
Table 2 various dose 8f and 8g are to the influence of S180 tumor-bearing mice tumour inhibiting rate, tumor weight and body weight a
Figure S2008101138564D00271
A) Arc cytosine arabinoside, NS=saline water, n=10, knurl weighs and weight increase is expressed as x ± SDg; Inhibiting rate is expressed as x ± SD%; B) compare p＜0.05 with 0.89 μ mol/kg group; C) compare p＜0.01 with 0.089 μ mol/kg group; D) compare p＜0.01 with 0.89 μ mol/kg and 0.089 μ mol/kg group.

Claims (7)

1. the compound of Formula I that has anti-tumor activity:
Figure FSB00000700120900011
general formula I
Wherein, AA 1Be selected from alanine residue, glycine residue, proline residue, glutamine residue, leucine residue, phenylalanine residue, Isoleucine residue, methionine residues, tyrosine residues, tryptophan residue, Xie Ansuan residue, lysine residue, Arg (NO 2) residue, Thr (Bzl) residue, Ser (Bzl) residue or Cys (CH 2-C 6H 4-OCH 3) residue; AA 2Be selected from alanine residue, glycine residue, proline residue, glutamine residue, leucine residue, phenylalanine residue, Isoleucine residue, methionine residues, tyrosine residues, tryptophan residue, Xie Ansuan residue, Lys (Z) residue, Arg (NO 2) residue, Thr (Bzl) residue, Ser (Bzl) residue or Cys (But) residue.
2. the general formula I I compound that has anti-tumor activity:
Figure FSB00000700120900012
general formula I I
Wherein, AA 1Be Asp (O Bzl) residue, AA 2It is Asp (O Bzl) residue; AA 1Be Glu (O Bzl) residue, AA 2It is Glu (O Bzl) residue.
3. method for preparing the said compound of Formula I of claim 1, this method comprises:
(1) the L-tryptophan transfer is become 1,2,3,4-Tetrahydrocarboline carboxylic acid;
(2) with 1,2,3,4-Tetrahydrocarboline carboxylic acid changes 1,2,3 into, 4-Tetrahydrocarboline benzyl carboxylate;
(3) amino acid is changed into amino-acid benzyl ester;
(4) amino acid is changed into the acid of N-t-butoxycarbonyl amino;
(5) with the acid of N-t-butoxycarbonyl amino and 1,2,3, the condensation of 4-Tetrahydrocarboline benzyl carboxylate generates N-t-butoxycarbonyl amino acyl-1,2,3,4-Tetrahydrocarboline benzyl carboxylate;
(6) with N-t-butoxycarbonyl amino acyl-1,2,3,4-Tetrahydrocarboline benzyl carboxylate hydrogenolysis generates N-t-butoxycarbonyl amino acyl-1,2,3,4-Tetrahydrocarboline carboxylic acid;
(7) with N-t-butoxycarbonyl amino acyl-1,2,3, the hydrolysis of 4-Tetrahydrocarboline benzyl carboxylate generates N-t-butoxycarbonyl amino acyl-1,2,3,4-Tetrahydrocarboline carboxylic acid;
(8) with N-t-butoxycarbonyl amino acyl-1,2,3,4-Tetrahydrocarboline carboxylic acid and amino-acid benzyl ester condensation generate N-t-butoxycarbonyl amino acyl-1,2,3, the 4-tetrahydrochysene carboline acyl aminoacid benzyl ester;
(9) with N-t-butoxycarbonyl amino acyl-1,2,3, the acidolysis of 4-tetrahydrochysene carboline acyl aminoacid benzyl ester promptly gets.
4. method for preparing the said general formula I I of claim 2 compound, this method comprises:
(1) the L-tryptophan transfer is become 1,2,3,4-Tetrahydrocarboline carboxylic acid;
(2) with 1,2,3,4-Tetrahydrocarboline carboxylic acid is transformed into N-tertbutyloxycarbonyl-1,2,3,4-Tetrahydrocarboline carboxylic acid;
(3) with N-tertbutyloxycarbonyl-1,2,3,4-Tetrahydrocarboline carboxylic acid and amino-acid benzyl ester condensation generate N-tertbutyloxycarbonyl-1,2,3, the 4-tetrahydrochysene carboline acyl aminoacid benzyl ester;
(4) with N-tertbutyloxycarbonyl-1,2,3, the acidolysis of 4-tetrahydrochysene carboline acyl aminoacid benzyl ester generates 1,2,3, the 4-tetrahydrochysene carboline acyl aminoacid benzyl ester;
(5) with the acid of N-t-butoxycarbonyl amino and 1,2,3, the condensation of 4-tetrahydrochysene carboline acyl aminoacid benzyl ester generates N-(N-t-butoxycarbonyl amino acyl)-1,2,3, the 4-tetrahydrochysene carboline acyl aminoacid benzyl ester;
(6) with N-(N-t-butoxycarbonyl amino acyl)-1,2,3, the acidolysis of 4-tetrahydrochysene carboline acyl aminoacid benzyl ester promptly gets.
5. a pharmaceutical composition of treating tumour is gone up the described compound of Formula I of claim 1 and the acceptable accessories of significant quantity and is formed by treatment.
6. a pharmaceutical composition of treating tumour is gone up the claim 2 described general formula I I compound and the acceptable accessories of significant quantity and is formed by treatment.
7. described compound of Formula I of claim 1 or the described general formula I I of claim 2 compound are in the purposes of preparation in the antitumor drug.
CN2008101138564A 2008-05-30 2008-05-30 N-(L-aminoacyl)-1, 2, 3, 4-tetrahydrochysene carboline acyl aminoacid benzyl ester, synthetic method and application thereof Expired - Fee Related CN101591335B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2008101138564A CN101591335B (en) 2008-05-30 2008-05-30 N-(L-aminoacyl)-1, 2, 3, 4-tetrahydrochysene carboline acyl aminoacid benzyl ester, synthetic method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2008101138564A CN101591335B (en) 2008-05-30 2008-05-30 N-(L-aminoacyl)-1, 2, 3, 4-tetrahydrochysene carboline acyl aminoacid benzyl ester, synthetic method and application thereof

Publications (2)

Publication Number Publication Date
CN101591335A CN101591335A (en) 2009-12-02
CN101591335B true CN101591335B (en) 2012-04-18

Family

ID=41406233

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008101138564A Expired - Fee Related CN101591335B (en) 2008-05-30 2008-05-30 N-(L-aminoacyl)-1, 2, 3, 4-tetrahydrochysene carboline acyl aminoacid benzyl ester, synthetic method and application thereof

Country Status (1)

Country Link
CN (1) CN101591335B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391323B (en) * 2011-10-18 2013-09-25 首都医科大学 Tetrahydro-beta-carboline derivative, preparation method thereof and use thereof
CN104231042A (en) * 2013-06-05 2014-12-24 首都医科大学 9-methoxymethyl-beta-carboline-3-formyl amino acid benzyl esters, and synthesis, antitumor activity and application thereof
CN105315324A (en) * 2014-06-10 2016-02-10 首都医科大学 1-(ethyl amino acid benzyl ester)-[beta]-carboline-3-carboxylic acid benzyl ester, preparation, activity, nano structure and application
CN105237616A (en) * 2014-06-10 2016-01-13 首都医科大学 Amino acid benzyl ester-modified beta-carbolines, activities, nanostructures, synthesis, and applications thereof
CN105218624A (en) * 2014-06-13 2016-01-06 首都医科大学 1-(ethylamino acid benzyl ester)-β-carboline-3-benzyl carboxylate, preparation, nanostructure, active and application
CN109912588B (en) * 2017-12-12 2020-06-19 首都医科大学 6-amino amido n-hexanoyl carboline benzyl carboxylate, preparation, activity and application thereof
CN109912589B (en) * 2017-12-12 2020-06-19 首都医科大学 Glutamine amido n-hexyl carboline carboxylic acid benzyl ester, preparation, activity and application thereof
CN109912587B (en) * 2017-12-12 2020-07-28 首都医科大学 Side chain protection amido n-hexanoyl carboline benzyl carboxylate, preparation, activity and application thereof
CN109912590B (en) * 2017-12-12 2020-06-19 首都医科大学 Amino acid and amino n-hexanoic acid modified carboline benzyl carboxylate, and preparation, activity and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1370778A (en) * 2001-12-20 2002-09-25 浙江医药股份有限公司新昌制药厂 Beta-tetrahydro carboline carboxylic acid, its RGD conjugate, their synthesis and medical application
CN1743326A (en) * 2004-09-03 2006-03-08 首都医科大学 Carboline carboxylate derivative, and its synthesizing method and use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1370778A (en) * 2001-12-20 2002-09-25 浙江医药股份有限公司新昌制药厂 Beta-tetrahydro carboline carboxylic acid, its RGD conjugate, their synthesis and medical application
CN1743326A (en) * 2004-09-03 2006-03-08 首都医科大学 Carboline carboxylate derivative, and its synthesizing method and use

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Guofeng Wu, et al..Toward breast cancer resistance protein (BCRP) inhibitors: design, synthesis of a series of new simplified fumitremorgin C analogues.《Tetrahedron》.2007,第63卷第5510-5528页. *
GuofengWu et al..Toward breast cancer resistance protein (BCRP) inhibitors: design
Jiawang Liu, et al..A new class of anti-thrombosis hexahydropyrazino-[1",2":1,6]pyrido-[3,4-b]-indole-1,4-dions: Design, synthesis, logK determination, and QSAR analysis.《Bioorganic &amp *
JiawangLiu et al..A new class of anti-thrombosis hexahydropyrazino-[1"
Medicinal Chemistry》.2006,第14卷第4761-4774页. *
Medicinal Chemistry》.2007,第15卷第5672-5693页. *
Ming Zhao, et al..Synthesis of new class dipeptide analogues with improved permeability and antithrombotic activity.《Bioorganic & Medicinal Chemistry》.2006,第14卷第4761-4774页.
Ming Zhao, et al..Synthesis of new class dipeptide analogues with improved permeability and antithrombotic activity.《Bioorganic &amp *

Also Published As

Publication number Publication date
CN101591335A (en) 2009-12-02

Similar Documents

Publication Publication Date Title
CN101591335B (en) N-(L-aminoacyl)-1, 2, 3, 4-tetrahydrochysene carboline acyl aminoacid benzyl ester, synthetic method and application thereof
AU650020B2 (en) Method for increasing blood-brain barrier permeability
CN101511823B (en) Multifunctional bioactive compounds
CN100427502C (en) Antineoplastic oligopeptide and its preparation method and application
CN101497584B (en) Isoquinoline-3-formyl amino acid formyl amino acid benzyl ester, as well as preparation and use thereof
CN104288779B (en) PEGization peptides dendrimer targeting drug delivery system of load gemcitabine and preparation method thereof
JPH0219397A (en) Novel linear derivatives of alginin vasopressin antagonist
JPH06501950A (en) Cyclic peptides, their preparation and their use as pharmacological compositions
CN103083680A (en) Polyethylene glycol (PEG)-amino acid oligopeptide-irinotecan combo and its medicinal composition
CA2020838C (en) Hemoregulatory peptides
CN1041159A (en) Peptide compounds
CN106883299A (en) Adipose tissue target polypeptide and its preparation method and application
JPH0288595A (en) Immunostimulant peptide, its production pharmaceutical composition containing peptide
CN103965458A (en) Polyethylene glycol-amino acid oligopeptide-dasatinib conjugate and pharmaceutical composition thereof
CN102174084B (en) Thymosin α1 active fragments cyclic peptide analogue and polyethylene glycol derivative thereof
EP3429575A1 (en) Carbonic anhydrase ix targeting agents and methods
CZ321199A3 (en) Derivatives of dolastatin-15 in combination with taxanes
EP4190361A1 (en) Polyethylene glycol conjugate drug, and preparation method therfor and use thereof
CN101591348B (en) Tetrahydrochysene carboline acyl aminoacid benzyl ester, preparation method and application thereof
CN1127514C (en) Antineoplastic peptides
CN105949278B (en) Substituted tetrahydrofuran water-soluble derivative and application thereof
US6596692B1 (en) Substance P analogs for the treatment of cancer
Pignatello et al. Conjugation of thymopentin (TP5) with lipoamino acid residues increases the hydrolytic stability and preserves the biological activity
CN108144043A (en) Eye Drops
JP2626682B2 (en) Novel peptide and angiotensin converting enzyme inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120418

Termination date: 20140530